Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 1 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15AN EXPLORATORY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF 
CANNABIDIOL ORAL SOLUTION (GWP42003P; CBD-OS) IN CHILDREN AND 
ADOLESCENTS WITH AUTISM SPECTRUM DISORDER
Study Code: GWND19189
IND Number:
EudraCT Number: 2020-002819-[ADDRESS_31006]
Histon
Cambridge CB24 9BZ
[LOCATION_008]
Tel: +44 (0) 1223 266 800
Fax: +44 (0) 1223 235 667
Confidentiality Statement
This document contains confiden tial information of GW Research  Ltd (GW) that must not be 
disclosed to anyone other than the recipi[INVESTIGATOR_31623].  This in formation cannot be used for any purpose other 
than the evaluation or conduct of the clinical i nvestigation without the prior written consent of 
GW.

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 2 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Investigator Agreement
I have read the attached clinical protoc ol entitled â€œAn exploratory, Phase 2, randomized, 
double-blind, placebo-controlled trial to investigate the safety and efficacy of cannabidiol oral 
solution (GWP42003-P; CBD-OS) in children and adolescents with Autism Spectrum Disorderâ€,
dated 24 November 2020 and agree to abid e by [CONTACT_3769].
I agree to comply with applicable regulatory requirement(s); the US FDA regulations relating to 
GCP and clinical trials, the EU  Clinical Trials Directive ( 2001/20/EC), the EU GCP Directive
(2005/28/EC) and subsequent applicable regulatory/statutory instruments, or the International Council for Harmonisation Tripartite  Guidelines for GCP where the EU Clinical Trials and GCP 
Directives do not apply, and to complete Form FDA 1572, if required. I accept responsibility for the overall medical care of patients during the trial and for all trial-related medical decisions.
I am not aware that any conflicts of interest, fi nancial or otherwise, exist for myself, my spouse 
[or legal partner] and dependent children and agree to confirm this in writing if required and 
update as necessary.I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of  the clinical investigation without the prior 
written consent of GW.
Center No:
Print name: [CONTACT_1782]:
Principal investigator (DD Month YYYY)
Signature:
[CONTACT_31725]: Date:
Medical Director (DD Month YYYY)
Signature:

[CONTACT_31726]: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 3 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep151 PROTOCOL SYNOPSIS
Trial Title An exploratory, Phase 2, rando mized, double-blind, placebo-controlled trial 
to investigate the safety and effi cacy of cannabidiol oral solution 
(GWP42003-P; CBD-OS) in children and adolescents with Autism 
Spectrum Disorder
Clinical Trial 
TypePhase 2
Indication Autism Spectrum Disorder
Objectives and Endpoints for 
Part BEfficacy Objective Efficacy Endpoints
xTo evaluate the efficacy of GWP42003-P, compared with placebo, in reducing symptom severity in children with ASD.Behavior
xABC Subscales
Social Communication
xVABS-3
Overall Condition
xCGI-I
xCGI-S
Safety Objective Safety Endpoints
xTo evaluate the safety of GWP42003-P, compared with placebo, in children with ASD.xAEs.
xClinical laboratory parameters.
xVital signs.
xPhysical examination procedures.
x12-lead ECG.
xC-SSRS.
 
 
 
 
  
 
 
 
 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 4 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15 
 
 
Trial Design This is an exploratory, Phase 2, double-blind, randomized, 
placebo-controlled, multisite trial, which will compare the safety and 
efficacy of a 10 mg/kg/day dose of GWP42003-P versus placebo in children and adolescents with ASD. 
Patients will be screened and if they meet eligibility criteria, they will be 
randomized to receive GWP42003-P or matching placebo in a 1:1 ratio. 
Patients will be stratified based on their age (6 to 11, 12 to 17), use of antipsychotics (on versus off), and region (North America versus Rest of the World). Patients will be adminis tered 5 mg/kg/day GWP42003-P or 
matching volumes of placebo for 1 week and then 10 mg/kg/day 
GWP42003-P or matching volumes of placebo for 11 weeks. At the end of treatment, patients will taper the medication over 1 week. 
In order to facilitate trial execution in the context of infectious diseases or 
other transmissible conditions (e.g., COVID-19), the trial will involve a combination of clinic, remote (includi ng a video call and a home nurse visit) 
and telephone visits, as specified in APPENDIX 1.
Sample Size 160 patients randomized to  allow for 144 evaluable patients 
(72 evaluable patients pe r arm) at trial end. 
Summary of Patient Eligibility CriteriaInclusion Criteria
For inclusion in the trial, patients must fulfill ALL of the following criteria:
xMale or female aged 6 to 17 years (inclusive). 
xPatient weight is at least 12 kg. 
xPatients (if possessing adequate understanding, in the investigatorâ€™s 
opi[INVESTIGATOR_1649]) and their parent(s)/legal representative are willing and able to give informed assent and consent for participation in the trial.
xPatient and their caregiver are willing and able (in the investigatorâ€™s opi[INVESTIGATOR_1649]) to comply with all trial requirements. 
xPatient has a diagnosis of ASD as per DSM-5 criteria for ASD, 
confirmed by [CONTACT_31656]-2 criteria (conduct ed within 2 years at the trial 
site or at screening by a qualified assessor). Note: During special circumstances (e.g., COVID-19 pandemic) where the ADOS-2 cannot be performed due to site restrictions (e.g., mandatory use of face 
masks) and an ADOS-2 conducted within 2 years at the trial site by a qualified assessor is not available, eligibility can be confirmed using: 1) an ADOS-2 performed within 2 years by a qualified assessor 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 5 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15(external to the site); 2) if 1) is not available, eligibility may be 
confirmed using the ADI-R at screening .
xCGI-S Â•4 (moderately ill) at sc reening and randomization.
xABC-IVXEVFDOHVFRUHÂ•DWVFUHHQLQJ .
x,4Â• at screening, or measured within 1 year of screening, using 
WASI-II.
xAll medications or interventions (including psychosocial interventions, 
dietary supplements, probiotics, sp eech therapy, etc.) for ASD related 
symptoms must have been stable for 4 weeks prior to screening and 
randomization, and the patient/caregiv er should be willing to maintain 
a stable regimen throughout the trial.
xPatients must have the ability to swallow the IMP, provided as a liquid solution.
xPatient and/or parent(s)/legal representative is willing to allow the responsible authorities to be notified of pa rticipation in the trial, if 
mandated by [CONTACT_1769].
xPatient and/or parent(s)/legal representative is/are willing to allow the patientâ€™s primary care practitioner (if they have one) and consultant (if they have one) to be notified of participation in the trial if the primary care practitioner/consultant is different from the investigator.
Exclusion Criteria
The patient may not enter the tr ial if ANY of the following apply:
xCurrent diagnosis of bipolar di sorder, psychosis, schizophrenia, 
schizoaffective disorder, or major depression (patients with depression 
in remission may be included).
xHas a diagnosis other than ASD that dominates the clinical 
presentation (e.g., ADHD).
xHas a progressive neurological condition.
xSeizures in the past [ADDRESS_31007], 
bupropi[INVESTIGATOR_2394], or efavirenz.
xCurrently using or has used recr eational or medicinal cannabis, 
cannabinoid-based medica tions (including Sativex
Â®, or 
Epi[INVESTIGATOR_8321]Â®/Epi[INVESTIGATOR_31624]Â®) within the 12 weeks prior to screening and is 
unwilling to abstain for the duration of the trial.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 6 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15xPatient has any known or suspected hype rsensitivity to cannabinoids or 
any of the excipi[INVESTIGATOR_31625], such as sesame oil.
xPatient has modera tely impaired hepatic func tion at screening, defined 
as serum ALT or AST > 2 Ã— ULN or TBL > 2 Ã— ULNâ€™
This criterion can only be confir med once the laboratory results 
are available; patients enrolled into the trial who are later found 
to meet this criterion must be screen-failed.
xPatient is male and fer tile (i.e., after puberty unless permanently sterile 
by [CONTACT_31657]) unless willing to ensure that they use male contraception (condom) or remain se xually abstinent during the trial 
and for 12 weeks thereafter.
xPatient is female and of childbearing potential (i.e., following 
PHQDUFKHDQGXQWLOEHFR PLQJSRVWPHQRSDXVDOIRUÂ• 12 consecutive 
months unless permanently sterile by [CONTACT_31658], bilateral 
salpi[INVESTIGATOR_1656], or bilateral oophorectomy) unless willing to ensure that they use a highly effective met hod of birth control (e.g., hormonal 
contraception, intrauterine device/ hormone-releasing system, bilateral 
tubal occlusion, vasectomized partner, sexual abstinence) during the trial and for 12 weeks thereafter.
xFemale patient who is pregnant (positive pregnancy test), lactating or 
planning pregnancy during the course of the trial or within [ADDRESS_31008] the patientâ€™s ability to take part in the trial.
xAny abnormalities identifie d following a physical examination of the 
patient that, in the opi[INVESTIGATOR_871], would jeopardize the 
safety of the patient if th ey took part in the trial.
xAny history of suicidal behavior (lifelong) or any suicidal ideation of type [ADDRESS_31009] at screening (not justified by a known concurrent medication).
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 7 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15xPatient has previously been randomized into this trial.
xPatient has plans to travel outside th eir country of residence during the 
trial, unless the patient has confirmation that the IMP is permitted in 
the destination country/state.
Criteria for WithdrawalThe patient must be withdrawn from th e trial if any of the following apply:
xAdministrative decision by [CONTACT_941] i nvestigator, GW or regulatory 
authority.
xDid not meet eligibility criteria.
xPregnancy.
xProtocol deviation that is cons idered to potentially compromise the 
safety of the patient.
xWithdrawal of patient consent/assent.
xWithdrawal of parent(s)/legal representative consent.
xALT or AST > 3 Ã— ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (> 5%).
xALT or AST > 8 Ã— ULN.
xALT or AST > 5 Ã— ULN for more than [ADDRESS_31010] > 3 Ã— ULN and(TBL > 2 Ã— ULN or INR > 1.5).
xNote: Prior to treatment discontinuation for the transaminase 
elevations noted above, the investig ator may choose to confirm the 
transaminase elevations by [CONTACT_31659], tests 
within 24 to 48 hours: ALT, AST, TBL, INR, % eosinophils, gamma-glutamyl transferase and alkaline phosphatase. Should the above 
transaminase elevation criteria be confirmed, the patient must be withdrawn from the trial. In cases where transaminase elevation withdrawal criteria are not met or confirmed, the dose of IMP or a 
concomitant medication with known hepatotoxicity may be reduced following discussion with the medical monitor.
xLost to follow-up.
The patient may also be withdrawn fro m the trial for any of the following:
xPatient noncompliance.
xAE (including clinically significant laboratory result) which, in the 
opi[INVESTIGATOR_871], woul d compromise the continued safe 
participation of the patient in the trial.
xPatient cannot tolerate a dose level of 5 mg/kg/day.
xAny evidence of use of drugs of abuse or drug diversion.
xSuicidal ideation or behavior of type 4 or 5 during the treatment 
period, as evaluated with the C-SSRS.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 8 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Investigational 
Medicinal Product: Formulation, Mode of Administration, Dose and RegimenGWP42003-P oral solution (100 mg/mL CBD  in sesame oil with anhydrous 
ethanol, ethanol (10% v/v) sweetener [s ucralose], and strawberry flavoring). 
Mode of administration: to be taken orally b.i .d. (morning and evening) 
using the syringe(s) provided, prefer entially with food i.e., within 30 
minutes after the end of a meal/snack. The time of IMP administration in relation to food should be kept consistent throughout  the trial. Volume of 
IMP to be determined by [CONTACT_4676]â€™s weight. 
Control Group Placebo to match GWP42003-P oral  solution containing sesame oil with 
anhydrous ethanol, sweetener (sucralose ), strawberry flavoring, and beta 
carotene. 
Procedures Before undergoing any assessments or obs ervations, the patientâ€™s 
parent(s)/legal representative is required to give written informed consent. In 
cases where the patient possesses adeq uate understanding, their assent will 
be taken, along with parental/le gal representative consent. 
Screening (Visit 1) assessments/procedures will include: 
xInformed consent/assent; eligibility criteria checks; demographics; medical history. 
xConcomitant medications/therapi[INVESTIGATOR_014]; AE/SAE review.
xTest for drugs of abuse. 
xFull physical examinations; incl uding height, weight, and BMI. 
x12-lead ECG. 
xHematology; biochemistry (incl uding liver chemistries); and 
urinalysis. 
xSerum pregnancy test (WOCBP only). 
xC-SSRS. 
xVital signs. 
xWASI-II (if required), ADOS-2 (if required, or ADI-R under special circumstances). 
xABC, CGI-S. 
Treatment Period (Visits 2 to 8) assessments/procedures will include (please refer to APPENDIX 1 for frequency of assessments): 
xRandomization 
xConcomitant medications/therapi[INVESTIGATOR_014]; AE/SAE review
xVital signs 
xFull physical examinations and weight 
x12-lead ECG
xHematology and biochemistry (in cluding liver chemistries) 
xC-SSRS
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 9 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15x  ABC, Vineland-3,  C
GI-S, CGI-I, 
xIMP dispensing
xIMP review
Note: Visits 3, 4, 6, and 10 ar e to be conducted by [CONTACT_31660] (Visit 9) assessments/procedures will include:
xConcomitant medications/therapi[INVESTIGATOR_014]; AE/SAE review
xC-SSRS
xVital signs
xHematology; biochemistry (including liv er chemistries) ; and urinalysis
xSerum pregnancy test (WOCBP only)
xIMP review
Follow-up (Visit 10) assessments/procedures will include:
xConcomitant medications/therapi[INVESTIGATOR_014]; AE/SAE review
Additional procedures to screen for the presence of or immunity against 
infectious diseases (such as body temp erature, sampling of nasal mucosal 
cells, or serology) may be  conducted at screening, at the beginning of each 
visit, or as needed, according to local guidance and policy.
Statistical ConsiderationsAll safety and efficacy data will be summarized and analyzed using appropriate statistical me thods. Questionnaires will be summarized at each 
visit along with the change from baseline,  where appropriate. As this is an 
exploratory trial, there will be no type  I error adjustments with all hypothesis 
testing performed at a 5% significance level.
Safety Monitoring CommitteeNot applicable.
Sponsor GW Research Ltd
Sovereign HouseVision ParkChivers WayHistonCambridge CB24 9BZ[LOCATION_008]

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 10 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Figure 1-1 Trial Design a nd Treatment Schematic

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 11 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Table of Contents
Title Page................................................................................................................... [ADDRESS_31011] Accountability .................................................... 34
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 12 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep155.3.[ADDRESS_31012] Administration .............................. 428.5 Access to Blinded Treatment Assignment ................................................................... 42
9 TRIAL PROCEDURES ...............................................................................43
9.1 Trial Procedures ...........................................................................................................  44
9.1.1 Informed Consent ...................................................................................................... 449.1.2 Contraception Requirements ..................................................................................... 449.1.3 Demographics ............................................................................................................ 45
9.1.4 Medical History ......................................................................................................... 459.1.5 Concomitant Medications  and Interventions ............................................................. 45
9.1.6 Physical Examination ................................................................................................ 459.1.7 Vital Signs .............................................................................................................. ... 45
9.1.8 12-Lead Electrocardiogram ....................................................................................... 469.1.9 Clinical Laboratory Sampling.................................................................................... [IP_ADDRESS] Pharmacokinetic Blood Sampling .......................................................................... 489.1.[ADDRESS_31013] y Management System ............................................ 48
9.1.11 Questionnaires and Assessments Co mpleted at Scheduled Visits ............................. 49
[IP_ADDRESS] Wechsler Abbreviated Scale of Intelligence Scale Second Edition ....................... [IP_ADDRESS] Autism Diagnostic Observ ational Schedule-2 ....................................................... 49
[IP_ADDRESS] Vineland Adaptive Behavior Scales, Third Edition ............................................... [IP_ADDRESS] Aberrant Behavior Checklist .................................................................................. 50
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 13 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep159.1.11.5 Clinical Global Impressions Questionnaire ........................................................... 50
[IP_ADDRESS] Pediatric Anxiety Rating Scale .............................................................................. [IP_ADDRESS] Repetitive Behavioral  Scale-Revised ..................................................................... 51
[IP_ADDRESS] Care-related Quality of  Life Questionnaire............................................................ 52
[IP_ADDRESS] Brief Observation of Social Communication and Speech Sample 
Acquisition ............................................................................................................. 52
[IP_ADDRESS] Columbia-Suicide Seve rity Rating Scale ............................................................... [ADDRESS_31014] Accountability .................................................... 53
9.1.13 Adverse Events ..........................................................................................................  53
9.2 Special Circumstances .................................................................................................. 53
10 WITHDRAWAL...........................................................................................55
11 URGENT SAFETY MEASURES ...............................................................5712 ADVERSE EVENT REPORTING .............................................................58
12.1 Definitions .................................................................................................................... 58
12.1.1 Adverse Event ........................................................................................................... . 58
12.1.2 Investigator ............................................................................................................ .... 58
12.2 Serious Adverse Events ................................................................................................ 5812.3 Reporting Procedures for Se rious Adverse Events ...................................................... 59
12.4 Pregnancy ................................................................................................................. .... 60
12.5 Causality Assessment ................................................................................................... 6012.6 Reporting Procedures for All Adverse Events ............................................................. 61
12.7 Follow-up Procedures fo r Adverse Ev ents ................................................................... 63
12.8 Potential Cases of Drug-Induced Li ver Injury ............................................................. 63
12.9 Notification of Safety Information to Investigat ors, Regulatory Authorities 
and IRBs/ECs ............................................................................................................... 64
13 STATISTICAL CONSIDERATIONS........................................................66
13.1 Sample Size, Power and Significance Levels .............................................................. 66
13.2 Interim Analysis .......................................................................................................... . 66
13.3 Analysis Sets ............................................................................................................. ... 67
13.3.1 Protocol Deviations ................................................................................................... 6713.4 General Considerations ................................................................................................ 6713.5 Accountability and Backgr ound Characteristics .......................................................... 68
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 14 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1513.5.1 Enrollment and Disposition ....................................................................................... 68
13.5.2 Baseline and Demograp hic Characteristics ............................................................... 68
13.5.3 Medical History .........................................................................................................  68
13.5.4 Concomitant Medication ........................................................................................... 6813.6 Endpoints and Statistical Methods ............................................................................... 6813.6.1 Efficacy Endpoints ..................................................................................................... 68
[IP_ADDRESS] VABS-3 .................................................................................................................. 6813.6.1.2 ABC ................................................................................................................... .... 69
[IP_ADDRESS] CGI-I and CGI-S .................................................................................................... 6913.6.2 Exploratory Endpoints ............................................................................................... 7013.6.2.1  .............................................................................................. 70
[IP_ADDRESS]  ............................................................................................... 70
[IP_ADDRESS]  ........................................................................................................... . 70
[IP_ADDRESS]  ............................................................ 70
13.6.3 Safety .................................................................................................................. ....... 71
[IP_ADDRESS] Treatment Compliance and Exte nt of Treatment Exposure ................................... 71
[IP_ADDRESS] Adverse Events....................................................................................................... 7 1
[IP_ADDRESS] Clinical Laboratory Data ........................................................................................ 7213.6.3.[ADDRESS_31015]/Independent Ethics Committee ........................................ 7415.4 Pre-trial Documenta tion Requirements ........................................................................ 75
15.5 Patient Confidentiality .................................................................................................. 7 5
16 ADMINISTRATIVE AND LEGAL OBLIGATIONS ..............................77
16.1 Protocol Amendments and End of Trial or Termination .............................................. 77
16.2 Trial Documentation and Storage ................................................................................. 7716.3 Trial Monitoring and Data Collection .......................................................................... 7816.4 Quality Assurance ........................................................................................................ 79

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 15 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1516.5 Compensation .............................................................................................................. . 79
16.6 Publication Policy.........................................................................................................  79
16.7 Intellectual Property Rights .......................................................................................... 80
16.8 Confidential Information .............................................................................................. 80
17 REFERENCES..............................................................................................81
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 16 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15List of Appendices
APPENDIX [ADDRESS_31016] of In-text Figures
Figure 1-1 Trial Design a nd Treatment Schematic.................................... 10
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 17 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15List of Abbreviations
ABC Aberrant Behavior Checklist Subscales
ABC-I Aberrant Behavior Checklist Irritability Subscale
ADHD Attention deficit hyperactivity disorder
ADI-R Autism Diagnostic Interview, Revised
ADOS-[ADDRESS_31017] Aspartate aminotransferase
BAC Blood alcohol content
b.i.d Twice daily
BMI Body mass index
BUN Blood urea nitrogen
Ca Calcium
CB Cannabinoid
CB1 Cannabinoid receptor type 1
CB2 Cannabinoid receptor type 2 
CBD Cannabidiol
CBD-OS GWP42003-P, Cannabidiol oral solution 
CGI Clinical Global Impressions
CGI-I Clinical Global Impressions - Improvement
CGI-S Clinical Global Impressions - Severity
CI Confidence interval
CIOMS Council for International Orga nizations of Medical Sciences
CK Creatinine kinase

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 18 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Cmax Maximum measured plasma concentration
COVID-[ADDRESS_31018] squares MDMA 3,4-Methylenedioxymethamphetamine
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 19 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15MMRM Mixed-effects repeated measures model
 
PI [INVESTIGATOR_31626]/INR Prothrombin time/International normalized ratio
PVD Pharmacovigilance Department
RTSM Randomization and Tr ial Management System
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SASÂ® Statistical Analysis System
SD Standard deviation
SOC System organ class
SRS Social Responsiveness Scale 
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TEAE Treatment-emergent adverse event
TBL Total Bilirubin
THC Ç»9-Tetrahydrocannabinol
TRP Transient receptor potential
ULN Upper limit of normal
US [LOCATION_002]
[LOCATION_003] [LOCATION_002] of America
VABS-[ADDRESS_31019] Ed., comprehensive 
interview form 
VAS Visual analog scale
VPA Valproic acid
WASI-II Wechsler Abbreviated Scal e of Intelligence Scale Second 
Edition
WD Withdrawal
WOCBP Women of childbearing potential

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 20 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Definition of Terms
Term Definition
Day [ADDRESS_31020].
Enrolled patient Any patient who has provided written informed consent/assent to 
take part in the trial.
International normalized
ratioA calculation made to standardize prothrombin time.
Investigational medicinal productTerm used to describe both investigational active product and 
reference therapy (placebo).
Investigator Trial principal investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a formally dele gated trial physician.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 21 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep152 OBJECTIVES AND ENDPOINTS
Efficacy Objective Efficacy Endpoints
xTo evaluate the efficacy of GWP42003-P, 
compared with placebo, in reducing symptom severity in children with ASD.Social Communication
xVABS-3
Behavior
xABC Subscales
Overall Condition
xCGI-I
xCGI-S
Safety Objective Safety Endpoints
xTo evaluate the safety of GWP42003-P, 
compared with placebo, in children with 
ASD.xAEs.
xClinical laboratory parameters.
xVital signs.
xPhysical examination procedures.
x12-lead ECG.
xC-SSRS.
 
 
 
  
 
 
 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 22 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep153 BACKGROUND AND RATIONALE
3.[ADDRESS_31021] approximately 1 in every 54 children aged 8 years 
and is reported to occur in all racial, ethnic, and socioeconomic groups1. Associated comorbid 
symptoms can include intellectual disabilit y, language impairment, motor abnormalities (for 
example, motor delay, hypotonia,  catatonia and deficits in c oordination), gastrointestinal 
problems, sleep disorders, psychiatric comorbidities (most commonly anxiety and depression) 
and behavioral dysregulation such  as aggression, impulsivity, irr itability, and self-injurious 
behavior2. Autism Spectrum Disorder is approximate ly 4 times more common in boys than in 
girls1.
Autism Spectrum Disorder is diagnosed through developmental screening (18 and 24 months, 
although additional screening might be  needed if a child is at high risk for ASD [e.g., an affected 
sibling] or if symptoms are present) and comprehensive diagnostic ev aluation. Diagnostic tools 
usually rely on parentsâ€™ or caregiversâ€™ desc riptions of their childâ€™s development and a 
professionalâ€™s observation of the childâ€™s behavior2,3.  
There is currently no single st andard treatment for ASD. Curre nt options for these patients 
include early intervention services, behavioral management therapy, educ ation and school-based 
therapi[INVESTIGATOR_014], nutritional therapy, a nd medication treatment. Medications are often used to manage 
certain behaviors, such as irr itability, aggression, and self-injury3,4. To date, the US FDA has 
approved 2 drugs for treating irritability associated with  ASD (risperidone [RISPERDALÂ®] and 
aripi[INVESTIGATOR_4253] [ABILIFYÂ®]); however, there are no approved drugs for the treatment of the core 
ASD symptoms (repetitive behavior; communication and social issues). Selective serotonin 
reuptake inhibitors (fluoxetine [PROZACÂ®], fluvoxamine [LUVOXÂ®], sertraline [ZOLOFTÂ®], 
and clomipramine [ANAFRANILÂ®]) can help to reduce repetitive behaviors and increase social 
contact, yet these drugs carry an FDA black box warning regarding potential increased risk of 
suicidal thoughts or attempts in  children and adolescents. Anti-ep ileptic drugs are also required 
in patients with seizures.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 23 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep153.2 Cannabidiol Background
GWP42003-P is the substance code for the IM P, purified CBD under development by [CONTACT_31661] a number of conditions, incl uding childhood onset epi[INVESTIGATOR_31627]. 
GWP42003-P is extracted from Cannabis sativa  L. plants, has a defined chemical profile, and 
contains consistent leve ls of CBD as the principal phytoca nnabinoid. Extracts from these plants 
are processed to yield pure ( Â•&%'WKDWW\SLFDOO\FRQWDL QVOHVVWKDQZZ7+& . 
The pure CBD is subsequently dissolved in exci pi[INVESTIGATOR_31628]. 
Cannabidiol demonstrates anticonvul sant, antipsychotic, anxiolytic, neuroprotective, antioxidant, 
and anti-inflammatory activity5.Anti-seizure effects of GWP42003- P have been demonstrated in 
clinical trials of childhood onset epi[INVESTIGATOR_31629]6and GWP42003-P has received FDA approval and 
by [CONTACT_31662] 
2 years of age and older (EMA approval is for treatment in conjunction with clobazam).
Cannabidiol possesses very low affinity and lacks appreciable functional activity at CB 
receptors; CB1 and CB26. In addition, CBD does not signifi cantly interact with enzymes 
responsible for the synthesis and degradation of endocannabinoids, at clinically relevant 
concentrations7,8. Other data exist describing th e polypharmacology of CBD at multiple 
7-transmembrane receptor systems, ion channels, transporters and enzymes7,8although this is 
often at concentrations (> 10 Â—M) that are unlikely to be clinically relevant.
At least [ADDRESS_31022] is modulation of 
intracellular Ca2+ mobilization via antagonism of GPR 55 and/or activati on (and subsequent 
desensitization) of TRP channels, particularly TRPV 16. The second is inhibition of adenosine 
reuptake6.
Importantly, CBD does not produce THC-like euphoric effects. 
 Cannabidiol oral solution has been studied in placebo-controlled clinical  trials as adjunctive 
treatment of seizures associated with LGS and DS  and is being used on a compassionate basis, as 
part of a series of expanded access IND applica tions in variety of refractory epi[INVESTIGATOR_31630], 
mainly in pediatric patients. This meaningful c linical trial exposure has yielded safety data on 
over 1,419 unique patients with epi[INVESTIGATOR_31631], with 391 patients with more  than 1 year of continuous 
exposure. 
In general, the key risks identified from the c linical development program for LGS and DS are 
broadly expected to be the same for the AS D population â€“ as the patient demographics and 
comorbidities have a significant amount of overlap. It  is important to note that several of the key 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 24 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15risks for CBD-OS are dose related, as such the lower doses planned for the current trial may 
improve the tolerability of CBD-OS:
Hepatocellular injury is anticipated to be an important risk for CBD-OS in ASD patients, 
although to date the transaminase elevations obs erved with CBD-OS trea tment have generally 
been asymptomatic, with no Hyâ€™s law cases re ported from any source. The proposed dose level 
of 10 mg/kg/day may provide an improved tolerability compared to the 10 and 20 mg/kg/day doses employed in the LGS and DS program. Furthermore, the transaminase elevations in LGS and DS patients were markedly more frequent and of a greate r magnitude in patients taking 
concomitant VPA. Of note, VPA use is expected  to be less frequent in the ASD population than 
in the LGS and DS populations, providing an add itional avenue to an imp roved tolerability to 
CBD-OS with respect to potential hepatocellular injury. 
Somnolence type events are anticipated to be  important risks for CBD-OS in ASD patients; 
however, from experience in LGS and DS patient s, such events were manageable, and only a 
minority needed to discontinue CBD-OS. Dose ad justment should help miti gate any events of 
somnolence and sedation if needed. The somnolence may also diminish with repeated dosing 
over time.
Cannabidiol oral solution has been shown to cause loss of weight in clinical trials, however the 
incidence of a significant loss of weight (> 5%) was noted to be similar between the CBD-OS 
dose of 10 mg/kg/day and placebo in placebo-co ntrolled trials. There was no impact on growth, 
as measured through BMI or height in these trials. 
In DS/LGS studies, aggression was reported in 2.2% of patients in th e 10 mg/kg/day group while 
irritability was reported in 7.2% of patients in the 10 mg/ kg/day group. The majority of cases 
reported were of mild or moderate severity with only few cases leading to withdrawal from these 
trials.
A higher incidence of pneumonia was noted w ith CBD-OS in LGS and DS controlled trials, 
although incidence does not appear to be dose rela ted, majority of patient s has risk factors for 
pneumonia and no plausible mechanism has been identified. 
Rash has been reported more of ten in CBD-OS patients compared with placebo patients in the 
controlled trials in LGS and DS. Importantly, none showed syste mic involvement or involvement 
of mucous membranes; generally, the rash events have be en self-limiting without serious 
outcomes. 
For further information on CBD-OS and current safety information please refer to the IB
6.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 25 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep153.[ADDRESS_31023] treatment for ASD. 
Both FDA-approved agents (risperidone [RISPERDAL in 2006] and aripi[INVESTIGATOR_4253] [ABILIFY in 
2009]) are indicated for irritability and associated  with potential for neurological and metabolic 
adverse effects; in Europe none of these drugs are specifically approved for use in ASD. There 
are no approved drugs for the treatment of the core ASD symptoms. 
CBD has the potential to modulate some of the pathophysiological mechanisms thought to 
underly ASD. CBD has also shown benef it in a range of pharmacological, brain 
injury-associated and genetic m odels of relevant medical cond itions, which exhibit behavioral
deficits similar to those seen in ASD, including deficits in social be havior, cognition, language, 
motor abnormalities,  and seizures6.
There is clinical literature on open-label investigations of cannabinoids extracts, containing CBD 
and THC, in ASD9,10,11,12. Data from these investigations  suggest some positive effects on 
behavior however data have generally been co llected using non-validated measures, flexible 
dosing schedules and variable cannabinoid content formulations, all of which render the results 
difficult to interpret. To date, data from 1 single placebo-controlled trial of a formulation containing CBD and THC in a ratio of 20:[ADDRESS_31024] of GWP42003-P on core symptoms ASD and major 
associated symptoms/comorbidities in children and adolescents. 
Efficacy Measures
The core symptoms of autism are the symptoms required for its diagnosis. Per DSM-5, the core 
symptoms cover 2 domains: persis tent deficits in social communication and social interaction
AND restricted, repetitive patterns of be havior, interests,  or activities. 
Effects on the core symptom â€˜persistent deficits in social communication and social interactionâ€™ 
will be evaluated using the Vineland-3. The challenges measuring social communication are well 
reported14. Measures such as the widely used SRS have been shown to be highly susceptible to 
placebo effect, other measures are limited in scope or age range. The Vineland is a well validated 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 26 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15scale with strong reliability that has been widely used in studies in children neurodevelopmental 
disabilities (although the majority of  published studies used the prev ious version Vineland-2). It 
was identified by [CONTACT_31663]14as an appropriate measure with  conditions with one of the 
limitations being possibly requiring a longer period to show sensitivity to change. Since, the 
Vineland-2, and in particular the socialization and communica tion domains, were reported to 
detect improvement over a 12-week treatment15. Importantly these [ADDRESS_31025] concern to caregivers16. The 
ABC-I is a well validated questi onnaire with excellent reliability17, which will be used to 
evaluate effects in these problem  behaviors. The ABC was designe d to measure treatment effects 
and has been used extensively in clinical trial in autism and other neurode velopmental disorders. 
The ABC-I in particular has been shown to be sensitive to treatment change, having been a primary endpoint for both risperidone and aripi[INVESTIGATOR_31632]. 
The remaining subscale scores of the ABC (social withdrawal, stereotypic behavior, 
hyperactivity/noncompliance,  and inappropriate speech) assess ot her aberrant behaviors relevant 
in ASD.
The CGI-S and CGI-I are widely used outcome measures in clinical trials with well accepted 
face validity
18.The CGI-I in particular is known to be sensitive to treatment  changes. Being a 
global measure, changes CGI-I reinforce the clinically meaningfulness of  changes reported in 
symptom specific outcomes. 
 
 
 
 
 
  
   
 
  
 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 27 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15 
 
 
 
 
 
 
 
 
3.3.
2 Choice of Dosing Regimen
Doses of up to 50 mg/kg/day GWP42003-P have been adminis tered in the GW clinical 
development programs for GWP42003-P. At the time of protocol authoring, a total of 
approximately 4,[ADDRESS_31026] received GWP42003-P from blinded and open-label GW-
sponsored trials and supportive programs (e xpanded access and other compassionate use 
programs), including patients with epi[INVESTIGATOR_002] (data cutoff date: Feb 2020). From  these data sources 
the following warnings and precautions were established: hepatocellular injury, somnolence and 
sedation, suicidal behavior and ideation, hypersensitivity reacti ons, and withdrawal of AEDs. Of 
note, routine liver monitoring is required with th e use of CBD-OS. To date, the available safety 
data collected showed that the reported AEs were usually mild or moderate in severity and resolved. There have been few withdrawals due to AEs. 
Efficacy of CBD against cognitive and social behavioral deficits in relevant animal models has 
been found over a range of doses from 2 to 200 mg/kg in a model a nd endpoint dependent 
manner
6, with the top dose of the tested dose range overlappi[INVESTIGATOR_31633] 50 to 200 mg/kg/day in nonclinical models6.It is therefore expected that clinical 
anticonvulsant doses (10 mg/kg/day and 20 mg/kg/da y as per studies in LGS or DS patients) 
should provide meaningful exposures  to explore efficacy in ASD. 
The doses used across the investigations reported in the literature referencing the use of CBD 
and THC in ASD are variable but mostly fall between 2 and 10 mg/kg/da y CBD. In particular, 
the target dose in the randomized, placebo-controlled trial9was 10 mg/kg day CBD (with a 
maximum CBD daily dose of 420 mg and an  average daily dose of 5.5 mg/kg/day). 
The GWND19189 trial will evaluate the efficacy a nd safety of 10 mg/kg/day CBD-OS (dosed as 
5 mg/kg/day b.i.d.) versus placebo. The dose of 10 mg/kg day was selected as it is within the 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 28 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15clinical therapeutic range for GWP42003-P in pediatric epi[INVESTIGATOR_25280] (LGS and 
DS).
The IMP solution contains 7.9% w/v anhydrous etha nol, which is required as sucralose is not 
soluble in sesame oil. The proposed dose of 10 mg/kg/day (administered as 5 mg/kg b.i.d.) will 
result in a BAC of 0.0065 g/L whic h equates to ethanol inges tion of 3.95 mg/kg. Both these 
amounts are well under the threshold for BAC of  0.125 g/L and ethanol ingestion of 75 mg/kg 
for patients 6 years and older. Twi ce daily (b.i.d) dosing is recommended for this clinical trial in 
accordance with the approved FDA label fo r CBD-OS (GWP42003-P) in the treatment of 
seizures associated with LGS or  DS in patients 2 years of age and older. Twice daily dosing 
should also minimize the potential risk of acute AEs related to C max. Further, peak trough ratios 
would be reduced, and improved pa tient adherence may reduce the potential clinical risks of a 
 patient/care psychological viewpoint. 
Concomitant administration of CBD-OS with a high fat meal resulted in a predictable increase in 
CBD exposure and less total subject  variability. The IMP will theref ore be taken preferentially 
with food i.e., within 30 minutes after the end of a meal/snack, and the time of IMP 
administration in relation to food should be  kept consistent throughout the trial. 
3.3.3 Benefit-Risk
There are no approved medications for the core symptoms of ASD and there are limited options 
for the management of comorbidities. 
Nonclinical and clinical data indicate that  CBD-OS may benefit pa tients with ASD (see 
Section 3.3 ).
The key risks identified from the CBD-OS clin ical development program for LGS and DS 
(described in Section 3.2 ) are broadly expected to be the same for the ASD population, as the 
patient demographics and como rbidities have a significant amount  of overlap. Importantly, the 
risk of raised transaminases is reduced in the context of this ASD trial, where the lower dose of 
CBD-OS will be used and VPA use is expected to be lower in this population. 
In the context of the anticipated benefit of CBD-OS in ASD patients, the key risks identified 
from the CBD-OS clinical deve lopment program in LGS and DS are acceptable given the 
proposed dose level of 10 mg/kg/day and the age range of 6 to 17 years. Thus, the overall 
benefit-risk for the development of CBD -OS in the ASD population is favorable. 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 29 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep153.4 Clinical Hypothesis
Treatment with GWP42003-P is associated with improvements in ASD symptom in children and 
adolescents as measured by [CONTACT_31664]-I, VABS-3 communication 
and socialization composite.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 30 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep154 EXPERIMENTAL PLAN
4.1 Trial Design
This is an exploratory, Phase 2, double-blind, ra ndomized, placebo-contro lled, multisite trial, 
which will compare the safety and efficacy of a 10/mg/kg/day dose of GWP42003-P versus 
placebo in children and adolescents with ASD. 
Patients will be screened  and if they meet eligibility criteria will be randomized to receive 
GWP42003-P or matching placebo in a 1:1 ratio. Patients will be stratif ied based on their age 
(6 to 11, 12 to 17), use of antipsychotics (on v ersus off), and region (North America versus Rest 
of the World). Patients will be administered 5 mg/kg/day GWP [ZIP_CODE]-P or matching volumes of 
placebo for 1 week and then 10 mg/kg/day GW P42003-P or matching volum es of placebo for 
11 weeks. At the end of treatment, patients will taper the medication over 1 week.A schematic ( Figure 1-1 ), presented at the end of Section 1 , depi[INVESTIGATOR_31634]. More 
detailed information on tr eatment and trial proced ures is provided in Section 8 and Section 9 , 
respectively. Eligible patients may be randomi zed 7 to 14 days after the screening visit (Visit 1), once all 
required assessments have been completed and laboratory results have been reviewed; if 
required, screening assessment may be spi[INVESTIGATOR_31635] 2 visits; however both visits must fall into the 
7 to 14 day window prior to randomization (Visit 2). One week and 2 weeks following 
randomization, there will be 2 safe ty telephone visits (Visit 3 and 4). The patient will return to 
the clinic or video call and home nurse visit, 4 weeks after randomization (Visit 5). Six weeks after randomization, there will be another safety call (Visit 6), and th en the patient will return for 
a clinic visit or video call visit (Visit 7) [ADDRESS_31027] 12 weeks after randomization (Visit 8) . If at any point it is decided to withdraw a 
patient from the trial, the patient should return to the clinic as soon as possible and complete Visit 8 procedures. At Visit 8, patients will commence to taper the medication (unless in case of withdrawal the medication was already discontinue d or continued dosing is  inadvisable, e.g., due 
to an AE). At the end of taper, the patient will return to the clinic or video call and home nurse 
visit (Visit 9). All patients will ha ve a follow-up safety telephone vi sit, 14 days after Visit 9 or 
Visit 8 (in case the patient did not taper the medication).
Visit windows are allowed as defined in the sc hedule of assessment. Visit 3, 4, 5, 6, 7, and 
8 days and windows are counted from the day of randomization (Visit 2). Visit 9 day and 
window is counted from the day of Visit 8. Vis it 10 day and window is counted from the day of 
Visit 9, or the day of Visit 8 (if the patient did not enter the taper period). 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 31 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep154.2 Number of Centers
Approximately 25 centers are expected to participate in this trial. Additional centers may be used 
in order to supplement recruitment. 
4.3 Number of Patients 
It is expected that 188 patients will be screened. With an anticipated screen  failure rate of 15%, it 
is expected that 160 patients will be rando mized to allow for 144 evaluable patients 
(72 evaluable patients per arm) at trial end. Th e sample size calculation is explained fully in
Section 13.1 . 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 32 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep155 INVESTIGATIONAL MEDICINAL PRODUCT
Please refer to the separate pharmacy manual for more detailed information on the IMP. 
5.1 GWP42003-P Oral Solution
GWP42003-P oral solution contains 100 mg/mL CBD dissolved in the excipi[INVESTIGATOR_31636] (10% v/v), with sweetener (sucralose), and strawberry flavoring ( Table 5.1-1 ).
Table 5.1-1 Formulation of GWP42003-P Oral Solution
Ingredients Quantity
CBD 100 mg/mL
Anhydrous ethanol 79 mg/mL
Sucralose 0.5 mg/mL
Strawberry flavor 0.2 mg/mL
Refined sesame oil make up to 1 mL
CBD = cannabidiol
5.2 Placebo
3ODFHERRUDOVROXWLRQFRQWDLQVWKH H[FLSLHQWVVHVDPHRLODQGDQ K\GURXVHWKDQROZLWKDGGHGÈ• -
carotene, sweetener (sucralose) and strawberry flavoring ( Table 5.2-1 ).
Table 5.2-1 Formulation of Placebo Oral Solution
Ingredients Quantity
Anhydrous ethanol 79 mg/mL
Sucralose 0.5 mg/mL
Strawberry flavor 0.2 mg/mL
Beta Carotene* Up to 0.1 mg/mL
Refined sesame oil make up to 1 mL
* È•-Carotene concentration can be varied up to a maximum of 0.01% w/v as required to provide a consistent 
yellow colored solution.
5.3 Packaging, Storage and Drug Accountability
5.3.1 Packaging and Labeling
The IMP will be manufactured, packaged, labeled and/or distributed by G-Pharm or delegated 
contractors. The IMP will be pr esented in 100 mL amber glass bo ttles with child resistant screw 
caps and packed in cartons. Sufficient IMP will be dispensed at each relevant visit considering the dose group and the weight of the patient. A unique identification number will be used to 
identify each carton and the IMP it contains. The unique identification number together with the PRN will permit full traceability of  manufacture, pack and labe l activities conduc ted at or on 
behalf of GW and the IMP information held on the RTSM system. GW will ensure that all IMP 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 33 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15provided is fully labeled and p ackaged. Label text will include the following information, as a 
minimum:
xSponsorâ€™s name [CONTACT_3816].
xProduct identification (e. g., â€œGWP42003-P or Placeboâ€).
xDose and/or Potency (e .g., â€œ100 mg/mL GWP42003-Pâ€).
xTrial code number.
xExpi[INVESTIGATOR_5695].
xStorage conditions.
xInstruction: â€œFor clinical trial use onlyâ€.
xInstruction: â€œKeep out of the reach and sight of childrenâ€.
xAny other information required by [CONTACT_31665].
In addition, any local country requirements in accordance with local Drug Law or Regulatory 
Requirement will be included in the final label text.
Directions of use, name, addre ss, and the telephone number of the investigator (or main contact 
[CONTACT_31666]) will be provide d separately to the 
caregiver. Caregivers will be instru cted to retain and carry this information with the patient at all 
times.
5.3.[ADDRESS_31028] be stored in compliance with th e local regulations for a controlled drug (if 
applicable to country). The sponsor must appr ove storage location and facilities. Temperature 
records of the clinical center storage location must be maintained (recording a minimum of 
Mondayâ€“Friday, excluding public holidays) from date of receipt of first shipment until end of 
trial dispensing period at each center. These records must contain at least the minimum and 
maximum daily temperatures and must be made available to th e appropriate GW personnel for 
review throughout the trial. Temperature during tr ansit of IMP to the center must be checked on 
receipt and compliance/noncompliance to the minimum and maximum recorded.
Should storage conditions deviate from these specified requirements, the GW trial monitor must 
be contact[CONTACT_31667]. IMP must be placed 
under quarantine until written conf irmation is received that the IMP is suitable for use.
Caregivers will be provided with instructions regarding home storage requirements for the IMP.

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 34 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep155.3.[ADDRESS_31029], at  the investigatorâ€™s center, who will check the amount received 
and condition of the drug (i.e., in tegrity, physical appearance, temp erature during transit). Details 
of the IMP received will be recorded in the IMP accountability record (see Section 5.3.4). The 
center will acknowledge the IMP receipt and will complete any receipt forms required. IMP will 
be dispensed and retu rned as detailed in Section 8.4. As directed, all supplies, including unused, 
partially used, or empty containers, will be returned to GW/depot or destroyed at a GW-approved 
site if agreed in writing by [CONTACT_31668]. 
5.3.[ADDRESS_31030] contain: 
xTrial code. 
xPRN, treatment number, date of receipt and quantity of IMP received.
xPatientâ€™s trial identification and or treatment number. 
xDate and quantity of IMP dispensed. 
xThe initials of the dispensing/dosing party. 
xDate and quantity of IMP returned to the investigator. 
xIMP expi[INVESTIGATOR_31637].
Refer to APPENDIX 1 for when IMP will be dispensed. Patients will be asked to return all IMP 
(used and unused) at each relevant visit ( APPENDIX 1 ). The site will check the returned IMP 
against the usage recorded in the medication diary. Any discrepancies will be discussed with the 
caregiver at the time of the visit and documented accordingly within the patientâ€™s source 
documents. 
The investigator must inform GW promp tly of all missing or unaccountable IMP. 
A record of returned IMP must be completed a nd included in the shipment of used and unused 
IMP to the relevant drug distribution depot. At the end of the trial, verification of reconciliation 
will be provided to GW.
These inventories must be made available for inspection by [CONTACT_31669]. 
Please refer to the separate pharmacy manua l for more detailed information on the IMP. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 35 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep155.3.[ADDRESS_31031]-trial access to the IMP will be provided.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 36 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep156 PATIENT ELIGIBILITY
Investigators are responsible for confirming pa tient eligibility and will be  required to maintain 
information about all screened pa tients (age, sex; as allowed per local regulations) and outcome 
of screening.
6.[ADDRESS_31032] fulfill ALL of the following criteria:
6.1.1 Male or female aged 6 to 17 years (inclusive).
6.1.[ADDRESS_31033] 12 kg.6.1.3 Patients (if possessing adequa te understanding, in the investigatorâ€™s opi[INVESTIGATOR_1649]) and their 
parent(s)/legal representative are willing and able to give informed consent for 
participation in the trial.
6.1.4 Patient is/and their caregiver are willing and able (in the investigatorâ€™s opi[INVESTIGATOR_1649]) to 
comply with all trial requirements.
6.1.5 Patient has a diagnosis of ASD as per DS M-5 criteria for ASD, confirmed by [CONTACT_31656]-2 
criteria (conducted within 2 year s at the trial site or at screening by a qualified 
assessor). Note: During special circumstances (e.g., COVID-19 pandemic) where the 
ADOS-2 cannot be performed due to site  restrictions (e.g., mandatory use of face 
masks) and an ADOS-2 conducted within 2 yea rs at the trial site by a qualified 
assessor is not available, eligibility can be confirmed using: 1) an ADOS-2 performed within 2 years by a qualified assessor external to the site; 2) if 1) is not available,
eligibility may be confirmed using the ADI-R at screening .
6.1.6 CGI-S Â• 4 (moderately ill) at sc reening and randomization.
6.1.7 ABC- ,VXEVFDOHVFRUHÂ•DWVFUHHQLQJ .
6.1.8 IQ Â• 70 at screening, measured within 1 year of screening, using WASI-II.
6.1.9 All medications or interventions (including psychosocial interventions, dietary 
supplements, probiotics, speech therapy, etc. ) for ASD related symptoms must have 
been stable for 4 weeks prior to screening and randomization, and the 
patient/caregiver should be willing to maintain a stable  regimen throughout the trial.
6.1.[ADDRESS_31034] the ability to swa llow the IMP provided as a liquid solution.
6.1.11 Patient and/or parent (s)/legal representative is wil ling to allow the responsible 
authorities to be notified of participation in the trial, if mandated by [CONTACT_1769].
6.1.12 Patient and/or parent (s)/legal representative is/are willing to allow the patientâ€™s 
primary care practitioner (if they have one) and consultant (if they have one) to be notified of participation in the trial if the primary care practitioner/consultant is different from the investigator.
6.2 Exclusion Criteria
The patient may not enter the trial if ANY of the following apply:
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 37 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep156.2.1 Current diagnosis of bipolar disorder, psychosis, schizophrenia, schizoaffective 
disorder or major depression (patients with  depression in remissi on may be included).
6.2.2 Has a diagnosis other than ASD that dominates the clinical presentation (e.g.,
ADHD).
6.2.[ADDRESS_31035], bupropi[INVESTIGATOR_2394], or efavirenz.
6.2.11 Patient is currently using or has used r ecreational or medicinal cannabis, cannabinoid-
based medications (includi ng SativexÂ®, or Epi[INVESTIGATOR_8321]Â®/Epi[INVESTIGATOR_31624]Â®) within the 
[ADDRESS_31036] > 2 Ã— ULN or TBL > 2 Ã— ULNâ€™.
6.2.14 This criterion can only be confirmed once the laboratory results are available; patients 
enrolled into the trial who are later found to meet this criterion must be screen-failed.
6.2.15 Patient is male and fertile (i.e., after puberty unless pe rmanently sterile by [CONTACT_25297]) unless willing to ensure th at they use male contraception (condom) or 
remain sexually abstinent during the trial and for 12 weeks thereafter.
6.2.16 Patient is female a nd of childbearing potential (i.e., following menarche and until 
EHFRPLQJSRVWPHQRSDXVDOIRUÂ•FRQVHFXWLYHPRQWKVXQOHVVSHUP DQHQWO\VWHULOHE\
hysterectomy, bilateral salpi[INVESTIGATOR_1656], or  bilateral oophorectomy) unless willing to 
ensure that they use a highly effec tive method of birth control (e.g., hormonal 
contraception, intrauterine device/hormone-releasing system, bilateral tubal 
occlusion, vasectomized partner, sexual abstinence) during the trial and for 12 weeksthereafter.
6.2.17 Female patient who is pre gnant (positive pregnancy test ), lactating or planning 
pregnancy during the course of the trial or within [ADDRESS_31037] the patientâ€™s ability to take part in the trial.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 38 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep156.2.[ADDRESS_31038] ize the safety of th e patient if they took 
part in the trial.
6.2.22 Any history of suicidal be havior (lifelong) or any suicidal  ideation of type [ADDRESS_31039] at screening (not justified by a known conc urrent medication).
6.2.25 Patient has previously been randomized into this trial.
6.2.26 Patient has plans to travel outside their c ountry of residence during the trial, unless 
the patient has confirmation that the IMP is permitted in the des tination country/state.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 39 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep157 PATIENT ENROLLMENT
Before patients may be entered into the trial, GW requi res a copy of the relevant centerâ€™s
IRB/EC written approval of the protocol, informed consent/assent forms and other patient
information material. Patients will be considered enrolled in the trial from the time of providing 
written informed consent/assent. All patients and/or parent(s)/legal representatives, where appropriate, must personally sign and date the consent/asse nt and, if allowed per local 
regulations, prior to any proce dures being performed (refer to Section 9.1.1  and Section 15.2 ).
7.1 Treatment Assignment
At the start of Visit 1, enrolled patients will be allocated a unique patient number. After 
confirmation of e ligibility at Visit 2, patients will be stratified and randomly allocated to 
GWP42003-P or matching volumes of placebo using the RTSM in a 1:1 ratio. GW will provide 
all IMP in a packed and labeled state and the RTSM will identify the pack number to be 
dispensed to the patient at each relevant visit, according to the treatment assigned in the 
randomization schedule. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 40 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep158 TREATMENT PROCEDURES
8.[ADDRESS_31040] Dos age, Administration and Schedule
For details regarding IMP formulations, see Section 5 . 
8.1.1 Dose Administration
GWP42003-P or placebo will be administered orally b.i.d. (morning and evening) using the 
syringe(s) provided, preferentially with food i.e., within 30 minutes after the end of a 
meal/snack. The first dose of GWP42003-P or pla cebo is taken at home in the evening. The time 
of IMP administration in relation to food should be kept consistent  throughout the trial. Volume 
of IMP to be determin ed by [CONTACT_4676]â€™s weight. 
The daily volumes of IMP solution to be taken will be calculated based on the patientsâ€™ weight 
and the dosing schedule will be provided to the caregiver. 
8.1.2 Dose Escalation, Adjustments, and Taper
Patients will be administered 5 mg/kg/day GWP42003-P or matc hing volumes of placebo for 
1 week and then 10 mg/kg/day GWP42003-P or matching volumes of placebo for 11 weeks. 
If an unacceptable AE develops at any time during the dose escalation or treatment periods, 
dosing should be reduced, at the i nvestigatorâ€™s discretion and in a blinded manner, until the event 
has resolved or is well tolerate d. The end of treatment taper sche dule should be used to guide 
dose adjustment. If required, dosing may be susp ended. Patients whose dose has been decreased 
should have their dose increased again, if the tole rability improves. Patients unable to tolerate the 
target dose may stay at a lower dose. If a patie nt cannot tolerate a dose of 5 mg/kg/day, the 
investigator should discuss with the medical mon itor whether patient con tinuation in the trial is 
recommended. Single dose volumes must be at least 0.1 mL. 
Transaminase elevations should be  medically managed by [CONTACT_31670], following discussion with the medical monitor, by [CONTACT_31671] (as per Section 10 ). For potential cases of 
drug-induced liver injury see Section 12.9 . 
Dose adjustments should be di scussed with the GW medical monitor. The final decision 
regarding dose adjustments should be taken by [CONTACT_093]. 
At the end of treatment, patient s will taper the medication in steps of -2.5 mg/kg/day every 
2 days. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 41 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep158.2 Concomitant Therapy
It is theoretically possible that GWP42003-P may modify the metabolism of other drugs 
(including AEDs) administered concurrently and there remains the possibility of 
pharmacological interactions between GWP42003-P and other concurrently administered drugs. 
Doses of any concomitant medications for ASD related symptoms must have been stable for at least [ADDRESS_31041] ma nagement. Decisions should be based on clinical 
symptoms and not plasma levels of concomitant medications. Further information on drug 
interactions can be found in the IB
6. Dose reductions for concomitant medications for ASD 
related symptoms are permitted on clinical grounds (e.g., due to AEs or transaminase elevations 
not meeting withdrawal criteria specified in Section 10  and Section 12.8  following discussion 
with the medical monitor). 
Any non-pharmacological therapi[INVESTIGATOR_014] (e.g., psychos ocial interventions, dietary supplements, 
probiotics, speech therapy, etc.) must also be stable up to [ADDRESS_31042] be recorded on the CRF. 
8.3 Prohibited Therapy During Trial Period
The following medications are prohibited for the duration of the trial beginning from the date of 
the screening visit. However, any patients ta king these medications after randomization should 
not be discontinued from treatment unless there are safety concerns. 
Care should be taken with drugs, or their metabolites, that are cytochrome P450 2C19 substrates, 
such as N-desmethylclobazam and are excluded as indicated below. Care should also be taken 
with drugs, or their metabolites, that are solely or primarily metabolized by [CONTACT_31672]-glucuronosyltransferase 1A9 and 2B7. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 42 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15xSirolimus, everolimus, temsirolimus, or tacrolimus. 
xClobazam. 
xOmeprazole or lansoprazole. 
xTolbutamide or warfarin. 
xRepaglinide, pi[INVESTIGATOR_051], rosiglitazone , montelukast, bupropi[INVESTIGATOR_2394], or efavirenz. 
xAny new medications or interventions for AS D related symptoms or changes in dosage, 
within 4 weeks or during the trial. 
xRecreational or medicinal cannabis or cannabinoid-based me dications (including Sativex, 
Epi[INVESTIGATOR_8321]/Epi[INVESTIGATOR_31624]) within the [ADDRESS_31043] the volume of solu tion on each treatment day in the diary. 
Patients should return all IMP (u sed and unused) at Visits 5, 8, and 9. The diary-reported dosing 
information will be checked and any discrepancies discussed with the caregiver at the time of the 
visit and documented accordingly with in the patientâ€™s source documents. 
Records of IMP accountability will be maintained according to Section 5.3.4 . 
8.5 Access to Blinded Treatment Assignment
The identity of IMP assigned to patients will be held by [CONTACT_31673]. The PI [INVESTIGATOR_12758], or 
his/her designee, is responsible for ensuring that information on how to access the RTSM system 
is available to the relevant staff in case of an emergency and unblinding is required. A patientâ€™s 
treatment assignment should only be unblinded when knowledge of th e treatment is essential to 
make a decision on the medical management of the patient. Unblinding for any other reason will 
be considered a protocol deviation. 
The investigator is encouraged to contact [CONTACT_31674]. However, to prevent delays to the investigat or or medical personnel 
responding to a potentially emergent situati on, unblinding of trial me dication will not be 
dependent upon the investigator receiving a pproval from the medical monitor (i.e., the 
investigator will be able to obtain the code break information independent of contact[CONTACT_31675]).
If the investigator does unblind, they must contact  [CONTACT_22840] [ADDRESS_31044] document the time, date and reason(s) for unblinding in the patientâ€™s medical 
notes and on the eCRF.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 43 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep159 TRIAL PROCEDURES
In order to facilitate trial execution in the context of infectious diseases or other transmissible 
conditions (e.g., COVID-19), the tria l will involve a combination of  clinic, remote (including a 
video call and a home nurse visit) and telephone visits, as specified in APPENDIX 1 . The 
investigator will determine in discussion with the caregiver by [CONTACT_765] 2 which visits will be performed at clinic or remotely. If at any point  there is motive for concern (e.g., AE of concern, a 
score of 4 or 5 in the C-SSRS) the patient should attend the clinic for fu rther assessment (either 
for a scheduled visit or for an unscheduled vis it). Unscheduled visits and assessments may be 
performed in the event of a safety concern, as deemed necessary by [CONTACT_093]. Data from any unscheduled visits or assessments should be reported on the unscheduled visits eCRF. 
When remote visits are agreed thes e may require (as per visit schedule): 
xA home nurse visit to collect blood and urine samples (including urin e dipstick), and vital 
signs. 
xA video call with the child and the caregiver to review IMP usage, adverse events, changes 
in concomitant medications, perform clinical interviews (C-SSRS and Vineland-3), and 
patient observation for assessm ent of CGI-S and CGI-I. 
xThe caregiver to complete the caregiver questionnaires electronically (ABC and ). 
xIMP review by [CONTACT_31676]/collection.
All events must take place within the protoc ol window; further guidance will be provided in a 
site manual. 
A list of the required trial procedur es is provided in the subsections that follow; refer also to the 
schedule of assessments ( APPENDIX 1 ). 
Patient functional assessments, i.e., th e WASI-II, ADOS-2,  
 should be performed prior to any invasive assessments being carried out. All 
assessments should reflect the patie ntâ€™s regular state; therefore, it should be ensured the patient 
had adequate time to settle prior to each assessment.
Assessments or tests that are not  done and examinations that are not conducted must be reported 
as such on the electronic CRF.
The location of the source data for study proced ures will be documented, per center, and filed in
the trial file; for further details see Section 16.2. 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 44 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep159.1 Trial Procedures 
9.1.1 Informed Consent
The parent(s)/legal representativ e of minor patients must pers onally sign and date the IRB/EC
approved ICF before any trial-specific procedures are performed or any patient-related data is 
recorded for the trial. In addition, assent will be taken (if allowed pe r local regulations) along 
with parent(s)/legal representative consent, using IRB/EC-approved forms. It is expected that the 
majority of patients w ill have sufficient understanding to provide assent; if the investigator 
assesses the patient as not ha ving sufficient understanding or co mmunication ability to provide 
assent, this must be clearly recorded in the pa tient notes. The explicit wish of a minor, who is 
capable of forming an opi[INVESTIGATOR_31638], to re fuse participation in 
or to be withdrawn from the clinical trial at a ny time must be considered by [CONTACT_093]. 
Investigators must record in the patient notes any reason(s) why a minor is unable to sign a form.
The original signed ICF should be retained and a copy provided to the patient and/or 
parent(s)/legal representative. Patients/parent(s) /legal representative will be given the option of 
being informed about the summary outcome and results  of the trial as part of the ICF. For further 
details, see Section 15.2 . 
9.1.2 Contraception RequirementsTo be eligible for the trial, female patients of  childbearing potential (i.e ., following menarche and 
XQWLOEHFRPLQJSRVWPHQRSDXVDOIRUÂ•FRQVHFXWLYHPRQWKVXQOHV VSHUPDQHQWO\VWHULOHE\
hysterectomy, bilateral salpi[INVESTIGATOR_31639], or bilateral oophorectomy) must have agreed that they are 
willing to use highly effective contraception for the duration of the trial and for 12 weeks 
thereafter. Highly effective methods of contra ception are defined as those, alone or in 
combination, that result in a low failure rate (i.e ., less than 1% per year) when used consistently 
and correctly
20. Such methods include hormonal c ontraception (the use of hormonal 
contraception must be supplemented with a barrier method [preferably male condom]), an 
intrauterine device/hormone-rel easing system, bilateral tubal oc clusion, vasectomized partner 
(provided that partner is the so le sexual partner of the trial pa tient and that the vasectomized 
partner has received medical assessment of the surgical success), or sexual abstinence21. 
To be eligible for the trial, male patients who are fertile (i.e ., after puberty unless permanently 
sterile by [CONTACT_31657]) must have agreed that they are willing to use male contraception (condom) or remain sexually abstinent during the tr ial and for 12 weeks thereafter. 
Abstinence, as referenced above, is only acceptable as true abstinence, i.e., when this is in line 
with the preferred and usual lifestyle of the patient. Pe riodic abstinence (calendar, 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 45 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15symptothermal, post-ovulation met hods), withdrawal (coitus inte rruptus), spermicides only, and 
the lactational amenorrhea method are not acceptable methods of contraception21. 
9.1.3 Demographics
The following information will be obtained for each patient: date of birth, sex, race, and ethnicity 
(as allowed per local regulations ). Details informing amount of time  spent with main caregiver 
will also be collected. 
9.1.4 Medical History
Relevant, significant medical history will be obtained at Screening (Visit 1) and is defined as any 
condition or disease that: 
xMay affect the condition under study. 
xIs ongoing on entry into the trial. 
xSuspected or confirmed COVID-19 infection (or other significant in fectious diseases) 
within 1 year prior to Screening (Visit 1). 
xInformation on ASD history, including known etiologies, will be recorded. 
9.1.5 Concomitant Medications and Interventions
Details of all current and recent medication/therapy (i.e., taken within the 14 days prior to the 
initial screening visit) will be recorded. All medications and interventions for ASD related symptoms must remain at stable doses throughout the trial; however, doses may be changed in response to a safety concern. Interven tions would include special diets. 
Any changes in concomitant medication or interventions during the trial must be recorded on the CRF at trial visits. Patients should stop taking any prohibited therapy prior to the screening visit, 
as defined in Section 8.3 . 
Testing for drugs of abuse will be performed at screening (Visit 1). 
9.1.6 Physical Examination
Physical examinations will include height (m easured once), body weight measurements, and 
BMI (Visit 1 only). 
9.1.7 Vital Signs
Vital sign measurements (body temperature, pulse rate, respi[INVESTIGATOR_1487]), including blood 
pressure taken in a sitting position at rest for [ADDRESS_31045] be recorded using 
the same arm throughout the trial, where possible. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 46 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep159.1.[ADDRESS_31046] review 
the ECG immediately (annotated, signed and dated)  and any abnormal findings considered to 
indicate significant medical hist ory or AEs must be recorded appropriately on the CRF. 
Additional ECG measurements can be taken at any time during the trial, if clinically indicated.
9.1.[ADDRESS_31047] the blood and urine samples in order to mitigate the risk that invasive procedures may 
cause the patient to become stressed, thereby [CONTACT_31677].
Laboratory tests will include he matology, biochemistry, coagulati on (Visit 1 only; thereafter 
only as an unscheduled assessment if ALT or AS T > 3 Ã— ULN) and urinalysis (provided urine 
can be obtained). Blood sample volume requirements and processing procedures will be detailed in a separate laboratory manual. 
Urine samples for biochemistry will be analyzed at the trial site (or by [CONTACT_31678]) by [CONTACT_2363] 
a dipstick with any relevant findi ngs being sent for further urinal ysis at the central laboratory 
(urinalysis, microscopy, culture, a nd sensitivity, as applicable). In cases where urine samples 
cannot be analyzed at the site (or by [CONTACT_31679]) due to local regulations, a full set of urine 
samples should be sent to the cen tral laboratory for analysis. Urine sample volume requirements 
and processing procedures will be detailed in a separate laboratory manual.
Urine samples for drugs of abuse will be sent to the central laboratory. 
The investigator and trial monitor will be provided with a list of the normal ranges used by [CONTACT_31680] a statement of accreditation (or 
similar) for the laboratory. Clinical laboratory sample parameters are detailed in Table 9.1-1 . 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 47 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Table 9.1-1 Biochemistry, Hematology, Urinalysis, and THC
Biochemistry
(Serum)aHematology
(Whole Blood)aCoagulation
(plasma)a,bUrinalysis
(Urine)cPregnancy 
Test 
(Serum)aDrugs of Abuse
(Urine)a
Alanine 
aminotransferase (ALT)Hematocrit Prothrombin 
time 
(PT/INR) Bilirubin Serum Amphetamines
Albumin Hemoglobin Blood Barbiturates
Alkaline phosphatase Mean cell volume Glucose Benzodiazepi[INVESTIGATOR_31640] (AST)Mean corpuscular 
hemoglobinKetones Cannabinoids
Calcium Platelets Protein Cocaine
Creatinine Red blood cell count Nitrites Methadone
Creatinine clearance White blood cell count 
with automated 
differentialpH Opi[INVESTIGATOR_31641] (CK) Specific 
gravityMDMA
Gamma-glutamyl 
transferaseUrobilinogen Methamphetamines
Glucose White blood 
cellsOxycodone
HDL-cholesterol Phencyclidine
Potassium Tricyclic 
antidepressants
Prolactin
Sodium
Total bilirubin
Total protein
Triglycerides
Urea (blood urea nitrogen [BUN])
HDL = high density lipoprotein; INR = international normalized ratio; 
MDMA = 3,4-methylenedioxymethamphetamine: THC = tetrahydrocannabidiol. 
a Analyzed at a central laboratory.
b Tested at Visit 1 only; thereafter only as an unscheduled assessment only if ALT or AST > 3 Ã— ULN
c Analyzed at the trial site (or by [CONTACT_31678]) by [CONTACT_2363] a dipstick (if allowed per local regulations).
Investigators at trial sites will be notified of safety laboratory test results. All laboratory results 
will be reviewed, and the reports signed and dated by [CONTACT_2413]. Any results considered to 
be of clinical significance must be addresse d and followed up as clin ically appropriate. The 
results of drugs of abuse screening will be reported back to the trial center for confirmation of eligibility. All laboratory results considered to represent an AE must be documented on the CRF. 
For reporting and follow-up of potential cases of drug-induced liver injury, see Section 12.[ADDRESS_31048] 
be repeated at regular intervals until it returns to normal, or until an investigator is satisfied that 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 48 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15the abnormality is not related to the IMP and needs no furthe r investigation. Blood sample 
volume requirements and processing procedures will be detailed in a separate laboratory manual; 
the maximum amount of blood taken during the course of the trial will not exceed 3 mL/kg of body weight within any 8-week period.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.1.[ADDRESS_31049] register in the eCRF 
at clinic visits in order to:
xObtain a patient number.
xRandomize a patient.
xObtain dispensing information.

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 49 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Training will be given to all sites prior to the start of the trial.
9.1.[ADDRESS_31050] and be able to attend clinic and vi deo call visits. For both caregiver-completed and 
investigator-completed questionnaires, the same assessors  should answer/complete the 
questionnaires/assessments throughout the trial to maintain consis tency. Investigators must be 
suitably qualified to perform each assessment/administer each questionnaire. Caregiver 
questionnaires are to be completed electr onically at site or at home. Physician 
interviews/assessments are to be completed at site or over a video call. Visit 2 and Visit 8 
assessments should always be completed at site.
If at any point of the trial the main caregiver ca nnot attend a visit (and th is cannot be avoided),
an alternate or backup caregiver may be used. Th is should only be done if all other options for 
the primary caregiver (i.e., scheduling issues) ha ve been exhausted. The alternative caregiver 
should not complete the .
[IP_ADDRESS] Wechsler Abbreviated Scale of  Intelligence Scale Second Edition
Patient direct assessment.
An IQ score Â•DWVFUHHQLQJ is required for eligibility, measured using WASI-II within 1 year 
of screening. If a score within 1 year of screen ing is not available the WASI-II will be conducted 
at the screening visit. The WASI-II provides a brief, reliable measure of cognitive ability suitable 
for individuals ages 6 to 90 years. The 2-subset form will be used. It evaluates Vocabulary and 
Matrix Reasoning and provides an estimate of gene ral cognitive ability .
The WASI-II (2-subset form) will be administered by [CONTACT_31681]
[IP_ADDRESS] Autism Diagnostic Observational Schedule-[ADDRESS_31051] user can obtain information that info rms diagnosis, treatment planning, and educational 
placement. The ADOS-2 consists of 5 modules, each of which is appropriate for children and 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 50 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15adults of differing developmental and language levels, ranging from nonverbal to verbally fluent. 
The individual being evaluated is  given only one module. The appr opriate module is selected and 
administered depending on the individualâ€™s verbal ability. The manual provides guidelines for 
selecting the most appropriate module and general instructions for administration and scoring 
and interpreting an individualâ€™s results. The ADOS-[ADDRESS_31052] be pe rformed face-to-face without the 
use of face masks, coverings, or shields. The ADOS-2 requires 40 to 60 minutes to administer. 
The ADOS-2 will be administered by [CONTACT_31682]. (Unless 
records of an ADOS-2 performed at the trial site within 2 years are available, in which case it does not need to be carried out at screening). 
[IP_ADDRESS] Vineland Adaptive Behavior Scales, Third Edition
The Vineland-3 measures the personal and soci al skills of individuals from birth through 
adulthood. Because adaptive behavior refers to an individualâ€™s typi[INVESTIGATOR_31642]-to-
day activities required for personal and social sufficiency, these scales assess what a person does, 
rather than what he or she can do. The Vinela nd-3 assesses adaptive behavior in 3 domains: 
Communication, Daily Living Skills, and Soci alization. Each domain is comprised of 
3 subdomains: receptive expression and written (communication); personal, domestic and community (daily living skills); Interpersonal re lationships, play and leisure and copying skills 
(socialization). There are several administration formats available. In this trial, the 
comprehensive review form will be used. The interview will be performed by [CONTACT_31683]. 
[IP_ADDRESS] Aberrant Behavior Checklist
The ABC was designed to assess the presence and severity of vari ous problem behaviors 
commonly observed in individuals diagnosed  with intellectual and developmental
16. It contains 
items that resolve onto 5 subscales: Irritability (15 items); Social Withdrawal (16 items); 
Stereotypic Behavior (7 item s); Hyperactivity/Noncompliance (16 items); and Inappropriate 
Speech (4 items). Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately 
serious problem), or 3 (severe problem). 
The ABC will be completed by [CONTACT_18629].
[IP_ADDRESS] Clinical Global Impressions Questionnaire
The CGI questionnaire was developed as a clinical trial measure to  provide a brief, stand-alone 
assessment of the clinicianâ€™s view of the patientâ€™s global functioning prior to and after initiating 
a trial medication18. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 51 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15The CGI questionnaire is split into 2 scales; the CG I-S scale and the CGI-I scale. The CGI-S is a 
7-point scale that requires the clinician to rate the severity of the patient's illness at the time of 
assessment, relative to the clinic ianâ€™s experience with patients who have the same diagnosis. The 
clinician is asked: Considering your total clinical experience with this particular population, 
how ill is the patient at this time? This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 
3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill.
The second section, the CGI-I, is a 7-point scale that requires the clinician to assess how much 
the patientâ€™s illness has improved or worsened relative to a baseline state at the beginning of the 
intervention. The clinician is asked: Compared to the patientâ€™s condition at admission to the 
project, how much has the patient changed? This is rated as: 1 = very much improved; 2 = much 
improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. 
The CGI will be completed by [CONTACT_093]. 
At Visits [ADDRESS_31053] with the child 
to facilitate assessment, to mimic as much as possible a clinic assessment. 
 
 
 
 
 
 
 
 
   
 
 
 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 52 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
9.1.
11.[ADDRESS_31054] thought about suicide 
(ideation), what actions they ha ve taken, and when, to prepare for suicide and whether and when 
they attempted suicide or began a suicide attempt that was either interrupted by [CONTACT_31684]. 
Suicidality will be assessed by [CONTACT_10540] C-SSRS via interview with the patient or, if the patient 
is not being cooperative, interv iew with the patientâ€™s caregiver assistance. If the interview is 
carried out with the caregiver this must be recorded and justified in the patient notes. 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 53 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15It is expected that some patient may engage in non-suicidal self-harming behavior. Self-harming 
behavior is not per se an exclus ion or withdrawal criteria unless it is carried out with suicidal 
intent. However, if an increase in non-suicidal self-harming behavior if observed this should be 
reported and an adverse event and the investigator should consider if it is safe for the patient to 
continue in the trial.
The C-SSRS is to be completed by [CONTACT_31685] a delegate who has completed the C-SSRS 
training within the past [ADDRESS_31055] Accountability
Records of IMP accountability will be maintained according to Section 5.3.4 . 
9.1.13 Adverse Events
Any adverse changes in the patientâ€™s medica l condition, following completion of the consent 
form by [CONTACT_18629], will be recorded on the eCRF as AEs, after questioning the caregiver 
further if necessary. All AEs occurring during the trial, whether attributed to the IMP or not, 
observed by [CONTACT_093], or reported by [CONTACT_18629], will be recorded in the eCRF. 
Any AE which meets SAE criteria should be reported as a SAE. 
SAEs must be reported to GW PVD within 24 hours of discovery or  notification of the event via 
recording in the eCRF. Adverse events inferring to hepatic enzymes increased, rash, pneumonia, cognitive disorders and 
self-injurious ideation or inte ntional self-injury ma y be considered as AESI by [CONTACT_31686]-up. 
Refer to Section 12 for definitions, procedures and fu rther information on AE reporting. 
9.2 Special Circumstances
During special circumstances (e.g., COVID-19 pandemic), the specific guidance from local 
public health and other competent authorities regarding the protection of individualsâ€™ welfare 
must be applied. In cases where patients are not ab le to perform all protocol-defined assessments 
due to special circumstances, the investigator must discuss with the medical monitor potential 
mitigation approaches. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 54 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15For the duration of such special circumstances, the following measures may be implemented for 
enrolled patients: 
xWhere the ADOS-2 cannot be performed due to site restrictions (e .g., mandatory use of 
face masks), and an ADOS-2 conducted within  2 years at the trial site by a qualified 
assessor is not available, eligibility can be  confirmed using: 1) an ADOS-2 performed 
within 2 years by a qualified assessor external to the site; 2) if 1) is not available, eligibility 
may be confirmed using the ADI-Rat screening.
xVisits or assessments may take place in a di fferent location or by [CONTACT_31687] (e.g., by 
[CONTACT_31688]) than defined in the protocol. 
xBiological samples may be collected and analyzed at a different location than defined in the 
protocol. Biological samples shoul d not be collected if they cannot be processed in a timely 
manner or appropriately stor ed until shippi[INVESTIGATOR_007]/processing. 
xWhere required, in order to collect the biologi cal samples, safety assessments (e.g., ECG, 
vital signs), or efficacy assessments as de fined in the protocol, visit windows may be 
extended up to a maximu m length of [ADDRESS_31056] this in the medical records.
The rationale (e.g., the specific limitation imposed by [CONTACT_31689]-specified assessment) and outcome of the discussion with the 
medical monitor will be documented in the medi cal record. Information on how each visit was 
performed will be recorded in the eCRF.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 55 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1510 WITHDRAWAL
In accordance with the Declaration of Helsinki25, the ICH Tripartite Guideline for GCP Topic 
E6(R1)26, the FDA regulations relating to GCP and clinical trials27,28,29, the EU Clinical Trials 
Directive30, the EU Good Clinical Practice/GCP Directive31and/or other applicable regulations, 
a patient has the right to withdraw from the trial at any time and for any reason, with no 
obligation to provide a reason, and without prej udice to his or her future medical care by [CONTACT_31690]. 
The patient must be withdrawn from th e trial if any of the following apply: 
xAdministrative decision by [CONTACT_31691], GW, or a regulatory authority. 
xDid not meet eligibility criteria.
xPregnancy. 
xProtocol deviation that is considered to co mpromise potentially the safety of the patient. 
xWithdrawal of patient consent/assent. 
xWithdrawal of parent(s)/le gal representative consent. 
xALT or AST > 3 Ã— ULN with the appearan ce of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, feve r, rash, and/or eosinophilia (> 5%).
xALT or AST > 8 Ã— ULN.
xALT or AST > 5 Ã— ULN for more than [ADDRESS_31057] > 3 Ã— ULN and(TBL > 2 Ã— ULN or INR > 1.5). 
Note: Prior to treatment disc ontinuation for the transaminase elevations noted above, the 
investigator may choose to c onfirm the transaminase elevations by [CONTACT_31692], test s within 24 to 48 hours: ALT, AST, TBL, INR, % eosinophils, gamma-
glutamyl transferase, and alkaline phosphatase. Should the above tran saminase elevation 
criteria be confirmed, the patient must be withdrawn from the trial. In cases where 
transaminase elevation withdrawal  criteria are not met or conf irmed, the dose of IMP or a 
concomitant medication with known hepatotoxicity may be reduced following discussion with the medical monitor.
xLost to follow-up. 
Patients may also be wit hdrawn from the trial for any of the following: 
xPatient non-compliance.
xAE (including clinically significant laboratory result) which, in the opi[INVESTIGATOR_871], would compromise the continued safe participation of the patient in the trial. 
xPatient cannot tolerate a dose level of 5 mg/kg/day. 
xAny evidence of use of drugs of abuse or drug diversion. 
xSuicidal ideation or behavior of type 4 or 5 during the trea tment period, as evaluated with 
the C-SSRS. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 56 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Should a patient request or decide  to withdraw from the trial, all efforts must be made to 
complete and report the observa tions as thoroughly as possible up to the date of withdrawal. 
Patients withdrawing due to an AE  should be followed up according to Section 12.[ADDRESS_31058] the patientâ€™s wishes.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 57 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1511 URGENT SAFETY MEASURES
The sponsor and investigator may ta ke appropriate urgent safety measures in order to protect the 
patients of a clinical trial against any immediate hazard to their health or safety. If such measures 
are taken by [CONTACT_093], they must notify GW immediately or at least within 24 hours of 
awareness. GW will report urgent safety meas ures to regulatory aut horities by [CONTACT_31693] 
24 hours of awareness, wherever possible, and will provide a written report to the regulatory 
authorities and IRB/EC within 3 days.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 58 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1512 ADVERSE EVENT  REPORTING
12.1 Definitions
12.1.1 Adverse Event
For the purposes of this trial an AE is defined as:
Any new unfavorable/unintended signs/symptoms (including abnorma l laboratory findings when 
relevant), or diagnosis or worsening of a pre-existing condition, which occurs following 
screening and at any point up to the post-treatment, safety follow- up visit, which may or may not 
be considered to be related to the IMP. Any even t that is the result of a trial procedure must be 
recorded as an AE. 
Surgical/Investigational procedures are not AEs. The medical reason for the procedure is the AE. 
Elective hospi[INVESTIGATOR_31643]-trial existing cond itions or elective procedures are not AEs. The 
exception may be if the patient has an AE duri ng hospi[INVESTIGATOR_31644] w ould be considered a SAE (refer to Section 12.2 ). 
If reporting a fatal event, the SAE term should be the underlying cause of the death (e.g., disease 
or medical condition leading to death). 
12.1.[ADDRESS_31059] the IM P is developed (e.g., change in 
dose, population, monitoring need, consent forms). Th is is particularly true for events that 
threaten life or function. Such SAEs will be reported promptly to regulatory authorities, 
applicable IRBs/ECs and investig ators (expedited reporting) by [CONTACT_31694]. 
An AE must only be classed as serious, i.e., a SAE, when the event falls into one of the 
following criteria:
xResults in death. 
xIs life-threatening*. 
xRequires inpatient hospi[INVESTIGATOR_31645]. 
xResults in persistent or significant disability/incapacity. 
xIs a congenital anomaly/birth defect. 
xIs medically significant**. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 59 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15*The term â€œlife-threateningâ€ in the definition of â€œseriousâ€ refers to an event in which the patient
was at risk of death at the time of the event; it does not refer to an event which, hypothetically,
might have caused death if  it were more severe.
**Medical and scientific judgmen t should be exercised in deciding whether SAE reporting is 
appropriate in other situations. Important medica l events may not be immediately life-threatening 
or result in death or hospi[INVESTIGATOR_31646]. These should also usually be 
considered serious. Examples of such events are intensive treatment in an  emergency room or at 
home for allergic bronchospasm, blood dyscras ias or convulsions that do not result in 
hospi[INVESTIGATOR_059], development of drug dependency or drug abuse, or positive COVID-[ADDRESS_31060] be recorded in the eCRF within 24 hours of discovery or notification of the 
event. GW PVD will be automatically notified that an SAE has been recorded. Any additional 
information required for a case (follow-up or corrections to the original case) will be requested 
by [CONTACT_31695].
The investigator should continue to document all AEs which occur up to the last formal 
follow-up observational period. If the investigator subsequently becomes aware of any deaths or 
a new IMP-related SAE after the last formal fo llow-up period of the trial, these should still be 
reported to the GW PVD.Any other problem discovered after the follow-up visit which is deemed to be an unexpected 
safety issue and is likely to have an impact on patients who have taken part  in the trial must be 
treated as an SAE and reported to the GW PVD. Such post-trial SAEs do not need to be recorded 
on the patientâ€™s eCRF if editing rights to the eCRF have been removed due to final trial data lock. GW PVD may request safety follow-up information after the final trial visit in order to 
investigate a potential safety issue.
Contact [CONTACT_31696] e provided at the front of the center files for all trial centers.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 60 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1512.4 Pregnancy
Any patient, or patientâ€™s partner, who becomes pregnant wh ile receiving the IMP, or within 
[ADDRESS_31061] be recorded in the eCRF within 24 hours of becoming aware. 
The GW PVD will be automatically notified that a pregnancy has been recorded. Any additional 
information required for a case (follow-up or corrections to the original case) will be requested 
by [CONTACT_31697]. The investigator is not obliged 
to actively monitor for any pregnancies that comm ence more than 90 days after the final dose of 
IMP. However, if the investigator becomes aware of a new pregnancy outside this time limit, 
then he/she should report it as above. The GW  PVD will follow-up for all pregnancy outcomes.
12.[ADDRESS_31062] be reported as such. The expression â€œreasonable causal 
relationshipâ€ is meant to convey in general that ther e are facts (evidence) or arguments to 
suggest a causal relationship.
The following question which must be answered by [CONTACT_3433] e investigator for all AEs is used to capture 
the reasonable causal relationship of an event to the IMP:
â€œIn your opi[INVESTIGATOR_31647] a plausible relationship to the IMP?â€ The answer is either â€œyesâ€ or
â€œnoâ€.
Events that start before the first dose of IMP (pre-treatment) should be considered as not causally 
related. Where a pre-treatment event worsens in severity following the first dose of IMP, a new 
event record should be entered into the eCRF.
Considering the explanation given above, investigators are strongly  encouraged to express their 
opi[INVESTIGATOR_31648]. For individual patients, the investigator is usually 
in the best position to assess the underlying susp ected cause of an AE. For all AEs and especially
SAEs, it is important that the investigator assess not only the possible role of the IMP but also 
other potential contributing factors. Factors for consideration of the underlying cause may 
include:
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 61 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15xMedical and disease history.
xLack of efficacy/worsening of treated condition.
xConcomitant or previous treatment.
xWithdrawal of IMP.
xProtocol-related procedure.
12.6 Reporting Procedures for All Adverse Events
All AEs (including SAEs) occurring during the tr ial will be reported on the running logs in the 
AE section of the eCRF. This includes all events from the time following screening up to and 
including the post-trial follow-up visit, whether or not attributed to IMP and observed by [CONTACT_31698].
The following information will need to be provided for all AEs:
A) Adverse Event (Diagnosis or Syndrome if Known, or Signs and Symptoms)
Where the investigator cannot determine a diagnosi s, signs or symptoms should be recorded in 
the AE section of the eCRF. Once a diagnosis has been determined the AE section of eCRF must 
be updated to reflect the diagnosis in replacement of the original symptoms. In circumstances 
where only a provisional diagnosis is possible (wor king diagnosis), the eCRF must be updated to 
reflect the provisional diagnosis in replacement of the original symptoms. In some circumstances 
it may be relevant for the inve stigator to include the symptoms alongside the diagnosis in the 
verbatim event description. However, the diagnosis (full or provisional) should be clearly stated,e.g., fever and malaise due to respi[INVESTIGATOR_1092].
B) Adverse Event Start Date and Stop Date
The start and stop dates of the event must be provided. All AEs require these fields to be 
completed in full. Partial dates or missing da tes are not normally acceptable and significant effort 
must be undertaken to obtain any unknown in formation. If a precise date is not known an 
estimated date should be provided instead. When a complete date cannot be given, record as 
much information as possible (i.e., month and year  or, in exceptional circumstances, just year). 
When the actual start date becomes known the eCRF must be updated to replace the previously recorded date.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 62 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15C) Outcome
The outcome of the event must be recorded accurately and classified into one for the following 
categories:
xRecovered/Resolved. 
xRecovered/Resolved with Sequelae. 
xNot Recovered/Not Resolved. 
xFatal. 
D) Severity
When describing the severity of an AE the te rms mild, moderate, or se vere should be used. 
Clinical judgment should be used when dete rmining which severity  applies to any AE. 
If the severity of an AE fluctuates day-to-day, e.g., a headache or constipation, the change in 
severity should not be recorded each time; inst ead, only the worst observed severity should be 
recorded with AE start and stop dates relating to the overall ev ent duration, regardless of 
severity. 
A severe AE is not the same as a SAE. For ex ample, a patient may have severe vomiting, but the 
event does not result in any of the SAE criteria above. Therefore, it should not be classed as 
serious. 
The severity of an AE will be recorded as one of the following: 
xMild: easily tolerated, does not interfere with normal daily activities, does not require 
intervention. 
xModerate: causes some interference with da ily activities; minimal, local or non-invasive 
intervention indicated. 
xSevere: daily activities limited or completely halted; intervention indicated.
E) Causality
See Section 12.6 above. 
F) Action Taken with Trial Medication
This question refers to the ac tion taken with the IMP due to an AE. The action with the IMP 
must be classed as:
xDose Not Changed. 
xDose Reduced. 
xDrug Interrupted. 
xDrug Withdrawn. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 63 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1512.7 Follow-up Procedures for Adverse Events
The investigator may be aske d to provide follow-up information to the GW PVD for any AEs 
reported or during the investigation of potential safety issues. Such  requests for additional safety 
information may occur after a patient has finished a trial. 
Additional information may also be requested by [CONTACT_31699] a patient experiences any adverse 
events that is considered an AESI, these include any events that may infer to hepatic enzymes 
increased, rash, pneumonia, cognitive disorders and self-injurious ideation or intentional self-
injury. 
AEs considered related to the IMP by [CONTACT_31700]. 
It will be left to the investigatorâ€™s clinical j udgment whether an AE is of sufficient severity to 
require the patientâ€™s removal from treatment. A patient may also voluntarily withdraw from 
treatment due to what he or she perceives as an intolerable AE. Further details of withdrawal are 
presented in Section [ADDRESS_31063] the investigator fo r additional follow-up information. 
12.8 Potential Cases of Drug-Induced Liver Injury
All investigational centers are required to submit to the GW PVD the laboratory results for any 
patient after randomization that meets the criteri a for the selected laboratory parameters as 
follows: 
xALT or AST > 3 Ã— ULN with the appearan ce of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, feve r, rash, and/or eosinophilia (> 5%).
xALT or AST > 8 Ã— ULN.
xALT or AST > 5 Ã— ULN for more than [ADDRESS_31064] > 3 Ã— ULN and (TBL > 2 Ã— ULN orINR > 1.5). 
These reports must be sent to the GW PVD via email for SAE reporting (see APPENDIX 2 ) 
within 24 hours of becoming aware of the results. In addition, please send a copy of the patientâ€™s 
baseline laboratory results with all reports to the GW PVD.
Abnormal values in AST and/or A LT concurrent with abnormal elev ations in TBL that meet the 
criteria outlined above are considered potential ca ses of drug-induced liver  injury and will be 
considered as protocol-defined criteria for withdrawal and important medical events. The 
investigator will arrange for the patient to return to the investig ational center as soon as possible 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 64 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15(within 24 hours of notice of abnormal results) for repeat assessment of ALT, AST, TBL, 
alkaline phosphatase and gamma-g lutamyl transferase levels, detailed history and physical 
examination; patients should be followed in this way until a ll abnormalities have  normalized (in 
the investigatorâ€™s opi[INVESTIGATOR_1649]) or returned to the baseline state. 
Elevations in ALT or AST > 3 Ã— ULN orTBL > 2 Ã— ULN alone are not considered potential 
cases of drug-induced liver injury, but will be  followed as detailed above, within 72 hoursâ€™ 
notice of abnormal results. If the patient cannot return to the investigational center, repeat 
assessments may be done at a local laborat ory and the results sent to GW PVD. 
12.9 Notification of Safety Information to Investigators, Regulatory Authorities 
and IRBs/ECs
In accordance with the EU Clinical Trials Directive30,relevant parts of the FDA Code of Federal 
Regulations32and any national regulations, GW will inform investigators, regulatory authorities 
and relevant IRBs/ECs of all re levant safety information. This will include the reporting of 
relevant SAEs and all S[LOCATION_003]Rs. 
This information will be provided through 3 sources: 
1) IB6: a compi[INVESTIGATOR_31649]. The IB is updated annually or when important new safety 
information becomes available. 
2) Development core safety information: this  document forms the safety section of the IB6, 
or is updated as an addendum to the IB6. This document is revised if necessary, when 
new important safety information becomes available (potentially up to a few times a year).
3) CIOMS reports: these reports are issued ev ery time a S[LOCATION_003]R is reported to GW. They 
provide information on individual case repor ts and are sent to all the regulatory 
authorities, the relevant central ECs which have approved the trial and investigators. As required, the investigator should notify th eir regional IRBs/ECs of SAEs or S[LOCATION_003]Rs
occurring at their center and other AE reports , i.e., CIOMS reports and any additional 
safety documentation received from GW, in accordance with local procedures.
In the [LOCATION_003], investigators are normally require d to report promptly to their IRBs/ECs all 
unanticipated problems involving risks to patient s, or others, including AEs that should be 
considered unanticipated problems. Based on current FDA guidance
28the following clarification 
is provided in determining what constitutes an unanticipated problem: 
In general, an AE observed during the conduct of a trial should be considered an unanticipated 
problem involving risk to patient s and reported to the IRB/EC, only if it were unexpected, 
serious, and would have implications for the cond uct of the trial (e.g., re quiring a significant, and 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 65 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15usually safety-related, change in  the protocol such as revising inclusion/exclusion criteria or 
including a new monitoring requireme nt, informed consent, or IB). An individual AE occurrence 
ordinarily does not meet these criteria because, as an is olated event, its implications for the trial
cannot be understood. 
The FDA guidance32states that, accordingly, to satisfy the investigatorâ€™s obligation to notify the 
IRB/EC of unanticipated problems, any investigat ors participating in a multicenter trial may rely 
on the sponsorâ€™s assessment and provide to the IRB/EC a report of the unanticipated problem 
prepared by [CONTACT_456]. 
GW will inform investigators, regulatory authorities and relevant IRBs/ECs of any safety issues 
or case reports that are considered to be unan ticipated and provide such  reports as mentioned 
above. It should be noted that a single S[LOCATION_003]R repor t notified to investigator s in the trial does not 
necessarily constitute an unanticipated problem unless identified by [CONTACT_31701].
As a minimum, the recipi[INVESTIGATOR_31650]. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 66 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1513 STATISTICAL CONSIDERATIONS
Further details of the proposed statistical analysis will be documented in SAP, which will be 
finalized prior to unblinding of the trial. Any deviations from the original SAP will be described 
in the final clinical study report.
13.1 Sample Size, Power and Significance Levels
Approximately 160 patient s will be randomized to receive GWP42003-P or matching volume of 
placebo on a 1:[ADDRESS_31065] at a 
Ä® -level, a total sample size of 160 patients ra ndomized to allow for 144 evaluable patients 
(72 patients per arm) at trial end will provide 80% power to detect a significant result assuming a 
WUXHWUHDWPHQWGLIIHUHQFH RIà¯—SRLQWVIRUWKH9$%6 -3 score in change from baseline to end of 
treatment between GWP42003-P a nd placebo. Allowing for a 10% drop-out rate, a minimum of 
160 patients need to be randomized into the trial.  Depending on the drop-out rate during the trial, 
this number may be increased to ensure a minimum of 144 evaluable patients at Week 12.
The size of this trial is more than enough to ensure > 99% power on the ABC-I scale assuming a 
common standard deviation for data of 8.27 with a true treatment difference in change from 
baseline to end of treatment between GWP [ZIP_CODE]-P and placebo of -8.26 and using a 2-sided 
K\SRWKHVLVWHVWDWDÄ® -level. As this is an exploratory tria l, no adjustments for the type I error 
were considered for these calculations. 
13.2 Interim Analysis
Interim evaluations for futility and superiority may be performed as part of DMC operations (see 
Section 14 ).   
Bayesian analysis of the key variables of interest may be performed to evaluate the probability 
that GWP42003-P is different than  placebo. Details of the evalua tion criteria will be provided in 
a separate Statistical Analysis or Simulation plan. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 67 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1513.3 Analysis Sets
The following analysis sets will be used for the statistical analysis:
Full Analysis Set
All patients who are randomized and receive at least [ADDRESS_31066] 1 dose of IMP in the trial will be included and analyzed 
according to the treatment received. Only patients for whom it has been confirmed that they did not take any IMP will be excluded from this safety analysis set. This analysis set will be 
used to report the safety data.
Per Protocol Analysis Set
If there are a sufficient number of significant protoc ol deviations in the trial, a PP analysis set 
may also be presented. Th e PP set is defined as:
All patients that are a subset of the FAS who have no major protocol deviations deemed to 
compromise the assessment of efficacy. Major protocol deviations will be identified and fully 
defined prior to unblinding of the trial. The PP analyses will only be conducted on efficacy endpoints.
Analysis sets will be id entified prior to the unblinding of the trial data.
13.3.1 Protocol Deviations
Protocol deviations will be listed and reasons for exclusion from the analysis sets (for major 
protocol deviations) will be summarized.
13.4 General Considerations
Unless stated otherwise, continuous variables will be summarized showing the number of non-
missing values (n), mean, SD, median, minimum and maximum and categorical variables will be summarized showing the number and percentage of patients falling in each category. Unless otherwise specified, tables  will be summarized by [CONTACT_21964].
For clinic visit-based endpoints ( unless otherwise specifie d), baseline is defined as the last record 
or measure collected prior to the firs t dose of IMP in the treatment period.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 68 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1513.5 Accountability and Backg round Characteristics
13.5.1 Enrollment and Disposition
All patients (screened, randomize d, withdrawn, etc.) will be accounted for in the enrollment and 
disposition summary tables.
13.5.2 Baseline and Demographic Characteristics
Age, sex, race, and ethnicity (as per local data protection laws in each specific country) and any
other demographic or baseline characteristics will be summarized by [CONTACT_2939], using appropriate summary statistics.
There will be no formal comparison of baseline da ta; that is, no statistical hypothesis testing.
13.5.3 Medical History
Previous and current medical conditions (including details of ASD history) will be summarized 
by [CONTACT_31702].
13.5.[ADDRESS_31067] placebo.
All safety data w ill be summarized using appropriate statistical methods.
13.6.1 Efficacy Endpoints
[IP_ADDRESS] VABS-3
The VABS-3 social and communication composite  (arithmetic mean of the social and 
communication domain scores), the adaptive beha vior composite, and individual domain scores 
will be analyzed. The VABS social and communication composite score is a key interest.
The change from baseline in social and communication composite score for VABS-3 will be 
summarized by [CONTACT_31703].
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 69 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15The change from baseline in social and communication composite score for VABS-[ADDRESS_31068]. An unstructured covariance matrix will be used to estimate the variance-covariance 
structure within patients across time points. If convergence is not obtained, then other covariance 
structures to be used will be specified in the SAP. Objective criteria for assessing normality assumptions and proposed alternative anal yses will be specified in the SAP. 
A Bayesian evaluation will also be ca rried out on the final data (see also Section 13.2 ).
From this analysis the LS mean estimates for ea ch treatment arm at each visit, along with the 
standard error and 95% CIs will be presented se parately. In addition, es timates of the treatment 
difference at each visit will be  presented along with standard er rors of the difference and 95% 
CIs. The main comparison of interest is the estimate of the treatment difference at Week 12. 
The change from baseline in adaptive behavior composite score and for each individual domain 
will be summarized and analyzed as described above for the social and communication 
composite score.
[IP_ADDRESS] ABC
All ABC subscales will be analyzed. The ABC-I subscale is of key interest.
ABC-I subscale scores will be summarized by [CONTACT_31704].
The change from baseline in ABC-I scores will be analyzed separately using a similar model as 
the one described for the social a nd communications composite endpoint. 
The other ABC subscales will be summarized and analyzed as described for the ABC-I subscale. 
[IP_ADDRESS] CGI-I and CGI-S 
Counts and proportion of pa tients within each category for the CGI-I and CGI-S scores will be 
produced separately by [CONTACT_31703]. These data will be analyzed separately using a 
GEE model approach. The model will include CGI-I as the dependent variable, with treatment 
arm and stratification fa ctors as fixed effects and baseline response as a covariate. The model 
will also include a repeated statement that allows to model the correlation of the dependent variable at different time points. A similar model will be fitted to the CGI-S data.
Proportion of patients at Week 12 â€˜minimallyâ€™, â€˜m uchâ€™ or â€˜very muchâ€™ improved, as well as 
â€˜muchâ€™ or â€˜very muchâ€™ improved, on the CGI-I score will be summarized by [CONTACT_31705]: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 70 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15will be analyzed using a logistic regression m odel with responder (impro ved/not improved) as 
the dependent variable, with trea tment arm and stratification factor s as fixed effects and baseline 
response as a covariate. The as sociated odds ratios together with the corresponding 95% CIs and 
p-values will be presented.
 
 
 
 
 
 
 
 
 
 
 
 

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 71 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1513.6.3 Safety
The following safety endpoints are used to support the safety objective and will be evaluated 
based on SASÂ®. For each endpoint, GWP42003-P will be comp ared with placebo as described in 
the following sections:
xAEs.
xClinical laboratory parameters.
xVital signs.
xPhysical examination procedures.
x12-lead ECG.
xC-SSRS.
All safety endpoints w ill be summarized by [CONTACT_31706].
[IP_ADDRESS] Treatment Compliance and Extent of Treatment Exposure
Treatment compliance and exposure to treatment will be summarized.
[IP_ADDRESS] Adverse EventsAEs will be coded according to the Medical Dictionary for Regulatory Activities dictionary.
A TEAE is one that started, or worsened in severity or seriousness, following the first dose of 
IMP.
Descriptive presentations of TEAEs will be given by [CONTACT_31707]. The number of patients reporting at least [ADDRESS_31069] 1 event (N) and the percentage of patients with at least 1 event (%).
The following summaries will be produced as a minimum:
xAll-causality TEAEs.
xTreatment-related AEs.
xAll-causality TEAEs by [CONTACT_2074].
xAll-causality serious TEAEs.
xTreatment-related serious TEAEs.
xTEAEs reported as leading to permanent cessation of IMP.
xFatal TEAEs.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 72 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1513.6.3.3 Clinical Laboratory Data
Clinical laboratory data will be  summarized at screening, baselin e, and at each time point during 
the treatment period using appropriate summary statistics. Categorical shift tables will be 
presented, showing the numbers of  patients with values outside  the normal range. Change from 
baseline will also be summarized by [CONTACT_765].
[IP_ADDRESS] Vital Signs, 12-Lead Electrocardiogram, Physical Examination and 
Other Safety Data
Vital signs, ECG, physical examin ation data will be summarized for the safety analysis set, at 
screening, baseline and at each time point during the treatment peri od using appropriate 
summary statistics. Changes in the vital signs from baseline to end of treatment will also be 
summarized.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 73 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1514 DATA MONITORING COMMITTEE
A Data Monitoring Committee will be setup for ongoing unblinded data review. The DMC will 
not include any members of the study team. Op erations and constitution of the DMC will be 
detailed in a separate charter.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 74 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1515 REGULATORY AND ETHICAL OBLIGATIONS
15.1 Declaration of Helsinki
The investigator will ensure that this trial is conducted in full conformity with the current version 
and subsequent amendments of  the Declaration of Helsinki34, the ICH Tripartite Guideline for 
GCP Topic E6(R1)26, the EU Clinical Trials Directive30, the EU GCP Directive31and the 
clinical trial regulations adopting European Commission Directives into national 
legislation35,36,37,38. 
15.2 Informed Consent
An initial generic ICF/Initial master informed consent/assent forms will be prepared by [CONTACT_31708], who will tailor this for their center by [CONTACT_31709]â€™s contact [CONTACT_31710]. The clinical manager or delegate will communicate updates to the templa te by [CONTACT_31711]. The written inform ed consent/assent documents 
should be prepared in the language(s ) of the potential patient population. 
Before a patientâ€™s involvement in  the trial, the investigator is  responsible for obtaining written 
informed consent/assent (if allowed per local regulations and if applicable) from the patientalong with written parent(s)/legal re presentative consent after ade quate explanation of the aims, 
methods, anticipated benefits and potential hazards of the trial and before any trial-specific 
procedures are performed or any patient-related data  are recorded for the trial. The patient and/or 
parent(s)/legal representative must have ample time to consider the information provided before giving written consent. More specific definitions of â€˜ample timeâ€™ may be in force if required by 
[CONTACT_1202]/ECs or local regulations. 
The acquisition of informed consent/assent must be documented in the patientâ€™s medical records 
and the ICF must be signed and personally dated by [CONTACT_102] a nd/or parent(s)/legal 
representative (as applicable) and by [CONTACT_31712]/assent
discussion. The original signed ICF/assent should be retained and a copy provided to the patient
and/or parent(s)/le gal representative. 
15.[ADDRESS_31070] /Independent Ethics Committee
A copy of the protocol, proposed ICF, master ICF, other patient info rmation material, any 
proposed advertising material a nd any further documentation request ed must be submitted to the
IRB/EC for written approval. GW must receive a copy of the written approval of the appropriate 
version of the protocol and ICF before recruitment of patients into the trial and shipment of IMP. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 75 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15The investigator must submit and, where necessary, obtain approval from the IRB/EC for all 
subsequent protocol amendments and change s to the informed consent document. The 
investigator must notify the IRB/EC of devia tions from the protocol, SAEs occurring at the 
center and other AE reports received from GW, in accordance with local procedures.
The investigator will be responsible for obtaining annual/ongoing IRB/ EC approval/renewal 
throughout the duration of the trial. Copi[INVESTIGATOR_31651]â€™s reports and the IRB/EC
continuance of approval must be sent to GW. 
15.4 Pre-trial Documentation Requirements
The investigator is responsible for forwarding the following documen ts to GW for review before 
allowing any patients to consent for entry into the trial: 
xSigned and dated protoc ol signature [CONTACT_3264]. 
xCopy of IRB/EC-approved ICF (including ve rsion number and date ) and other patient
information material.
xCopy of the IRB/EC approval of the protoc ol, ICF forms (including version number and 
date) and other patient information material.
xUp to date curricula vitae a nd medical licenses (as per local regulations) of the PI [INVESTIGATOR_31652]-investigators.
xThe IRB/EC composition and/or written statement of the IRB/EC in compliance with the 
FDA regulations relating to GCP and clinical trials27,28,29,39, the EU Clinical Trials 
Directive30, the EU GCP Directive31,or the ICH Tripartite Guidelines for GCP Topic 
E6(R1)20where the EU Clinical Trials a nd GCP Directives do not apply. 
xSigned and dated laboratory nor mal ranges and documentati on of laboratory certification 
(or equivalent) unless using centr al laboratory arranged by [CONTACT_31694]. 
xSigned and dated clinical  trial agreement (including investigator indemnity insurance and 
financial agreement).
xForm FDA [ADDRESS_31071] ensure that the patientâ€™s anonymity is maintained. In the eCRFs or other 
documents submitted to GW, patient s should be identified by [CONTACT_31713]. Documents that are not for submission to GW, e.g., signed ICF, should 
be kept in strict conf idence by [CONTACT_093]. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 76 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15In compliance with the FDA regulations relating to GCP and clinical trials27,28,29,39and the EU 
Clinical Trials Directive30/ICH Tripartite Guidelines for GCP Topic E6(R1)26, it is required that 
the investigator and institution permit authorized  representatives of the company, the regulatory 
authorities and the IRB/EC have direct access to review the patientâ€™s original medical records for 
verification of trial-related pr ocedures and data. Direct acce ss includes examining, analyzing, 
verifying and reproducing any record s and reports that are important to the evaluation of the trial. 
The investigator is obligated to inform the patient that his/her trial-related records will be reviewed by [CONTACT_31714]-named representatives without  violating the confidentiality of the patient. 
All information concerning the IMP and operations of GW such as patent applications, formulae, 
manufacturing processes, basic sc ientific data or formulati on information supplied to the 
investigator by [CONTACT_31715]. The investigator will agree to use 
this information only in accomplishing the trial a nd will not use it for any other purposes without 
the written consent of the company. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 77 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1516 ADMINISTRATIVE AND LEGAL OBLIGATIONS
16.[ADDRESS_31072] be obtained for all protocol amendments and amendments to the informed 
consent document. The IRB/EC and regulatory authorities must be informed of all amendments 
and give approval for any substantial amendments. Amendments  for administrational changes 
can be submitted to the IRB/EC for information only. The investigator must send a copy of the approval letter from the IRB/EC to GW.
Both GW and the investigator reserve the right to terminate the trial, according to the clinical 
trial agreement. The investigator must notify the IRB/EC in writing of the trialâ€™s completion or early termination and send a c opy of the notification to GW. 
16.[ADDRESS_31073] of appr opriately qualified persons  to whom he/she has 
delegated trial duties. All persons authorized to make entries in and/or corrections to CRFs will 
be included on the delegation log. 
Source documents are original documents, data and records containing a ll protocol-specified 
information from which the patientâ€™s CRF data are obtained. These include, but are not limited 
to, hospi[INVESTIGATOR_1097], clinical and office charts , laboratory and pharmacy records, diaries, 
microfiches, radiographs and correspondence. The sour ce for each data point will be agreed with 
each center prior to patient recruitment. In the rare situations of data being recorded directly into 
the CRF in error, then the source data from the CRF should be transcribed into the patientâ€™s notes 
with appropriate signature [CONTACT_31727] a full audit trail. 
The investigator and trial staff are responsible for maintaining a comprehensive and centralized
filing system of all trial-related, essential documentation (as outlined in the ICH Tripartite 
Guidelines for GCP Topic R6[R1]
26, Section 8.2), suitable for inspection at any time by 
[CONTACT_31716]/or applicable re gulatory authorities. Elements should include: 
xPatient files containing completed CRFs, ICF forms and supporting copi[INVESTIGATOR_31653]. 
xTrial files containing the prot ocol with all amendments, IB, copi[INVESTIGATOR_10468]-trial
documentation (see Section 15.4 ) and all correspondence to and from the IRB/EC and GW.
xEnrollment log of all patients who consented to take part in the trial. 
xScreening and recruitment log of all patients screened and whether or not they were 
recruited into the trial (i.e., randomized and/or dosed with IMP). 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 78 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15xProof of receipt, IMP accountability record, return of IMP for destruction, final IMP
reconciliation statement and a ll drug-related correspondence.
In addition, all original source documents suppor ting entries in the eCRF s, and diary data must 
be maintained and be readily available.
Following completion or termination of a clinical trial, GW will initiate proper archive of clinical 
trial-related documentation and electronic record s generated by [CONTACT_1755]/or GW. All 
clinical trial-related documents and electronic records will be retained within an archiving system for a period dependent upon need and fo r a minimum of [ADDRESS_31074] retention. No trial document may be destr oyed without prior written ag reement between GW and the 
investigator. Should the investigator wish to a ssign the trial records to another party or move 
them to another location, he/she  must notify GW in writing of th e new responsible person and/or 
the new location. 
16.[ADDRESS_31075], inspecting 
the various records of the trial, e.g., CRFs and other pertinent data, provided that patientconfidentiality is respected.
The GW trial monitor, or designee, is responsible for inspecting (on site or remotely) the CRFs 
and available diary data at regular intervals th roughout the trial to verify adherence to the 
protocol, completeness, accuracy and consistency of th e data and adherence to local regulations 
on the conduct of clinical resear ch. The trial monitor must have  (direct or remote) access to 
patient medical records and other trial-related records needed to verify the entries on the CRFs. 
The investigator agrees to cooperate with the tr ial monitor to ensure that any problems detected 
in the course of these monitoring visits are resolved. 
To ensure the quality of clinical data across all patients and centers, a clinical data management 
review will be performed on patient data received at GW or a CRO. During this review, patient
data will be checked for consiste ncy, omissions and any apparent discrepancies. In addition, the 
data will be reviewed for adherence to the protocol and FDA regulations
27,28,29,39, ICH Tripartite 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 79 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Guidelines for GCP Topic E6(R1)26and all other applicable regulat ory requirements. To resolve 
any questions arising from the clin ical data management review process, data queries and/or 
center notifications will be sent to the center for completion and then returned to GW or the 
CRO, as applicable. 
16.4 Quality Assurance
In accordance with the FDA regulations27,28,29, EU Clinical Trials Directive30/ICH Tripartite 
Guidelines for GCP Topic E6(R1)26and the sponsorâ€™s audit plans, representatives from GWâ€™s 
Clinical Quality Assurance Department may select this trial for audit. Inspection of center
facilities, e.g., pharmacy, drug storage areas, laboratories, and review of trial-related records will 
occur to evaluate the trial c onduct and compliance with the protocol, the EU Clinical Trials 
Directive30/ICH Tripartite Guidelines for GCP Topic E6(R1)26and applicable regulatory 
requirements.
16.[ADDRESS_31076] of 
personal injury arising due to a patientâ€™s involvement  in the trial, providing that the trial protocol 
has been adhered to. This would include claims ar ising out of or relating to the administration of 
the IMP or any clinical intervention or proce dure provided for or required by [CONTACT_31717], providing there is no 
evidence of negligence on behalf of the investigator or their team. GW will not be liable for any 
claims arising from negligence on the part  of the investigator or their team.
16.[ADDRESS_31077] arising from this clinical trial are appropriately published and disseminated. 
They will coordinate this dissemination and ma y solicit input and assistance from the 
chief/principal investigators. A summary of the results of this trial will be made available on 
http://www.clinicaltrials.gov and http ://www.clinicaltrialsregister.eu/ (as applicable), as required 
by [CONTACT_31718].
The raw data from this trial may be obtained by [CONTACT_31719]. Should they wish, PIs are allowed to conduct their own analyses and 
are permitted to present such information along with  methods and results of  the clinical trial at 
symposia, national or regi onal professional m eetings and to publish it in theses or dissertations. 
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 80 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15All publications, e.g., manuscripts, abstracts, ora l/slide presentations or book chapters based on 
this trial, must be submitted to the GW Me dical Affairs Department and, as applicable, GW 
Publication Committee for corporate review before release. To ensure adequate time for GW to 
make comments and suggestions where pertinent, all such material should be submitted to them 
at least [ADDRESS_31078] 
party or made use of without the prior written consent of the other.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 81 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1517 REFERENCES
1Maenner MJ, Shaw KA, Baio J, et al. Prev alence of Autism Spectrum Disorder Among 
Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 
Sites, [LOCATION_002], 2016. MMWR Surveill Summ 2020; 69 (4): 1â€“12.
2Lai MC, Lombardo MV, Ba ron-Cohen S. Autism. Lancet, 2014;383:896-910.
3Howes OD, Rogdaki M, Findon JL, et al. Autis m Spectrum Disorder: consensus guidelines 
on assessment, treatment and research from the British Association for Psychopharmacology. 
J Psychopharmacol. 2018 January;32(1):3â€“29. doi:10.1177/0269881117741766.
4Sharma SR, Gonda X, Tarazi FI. Autism Spect rum Disorder: Classification, diagnosis and 
therapy. Pharma Thera. 2018;190:91â€“104.
5dos Santos RG, Hallak JEC, Le ite JP, Zuardi AW, Crippa JAS. Phytocannabinoids and 
epi[INVESTIGATOR_002]. J Clin Pharm Ther 2015;40(2):135â€“43.
6Investigatorâ€™s Brochure â€” CBD medicine . GW Research Ltd. Edition 12.1. October 2019.
7Ibeas Bih C, Chen T, Nunn A, Bazelot M, Dallas M, Whalley B. Molecular Targets of 
Cannabidiol in Neurological Disorders.  Neurotherapeutic s. 2015;12(4):699-730.
8Turner SE, Williams CM, Iversen L, Whalley BJ.  Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod. 2017; 103: 61â€“101
9Aran A, Cassuto H, Lubotzky A, Wattad N,  Hazan E. Brief Re port: Cannabidiol-rich 
cannabis in children with autism spectrum disorder and severe behavioral problemsâ€”a 
retrospective feasibility study. 2018; J Autism Dev Disord; https://doi.org/10.1007/s10803-018-3808-2
10Barchel D,  Stolar O, De-Haan T, et al. Oral cannabidiol use in children with autism
spectrum disorder to treat related symptoms and co-morbidities. 2019; Front. Pharmacol. 
9:1521.
11Bar-Lev Schleider L, Mechoulam R, Saban N, et al. Real life experience of medical cannabis 
treatment in autism: analysis of safety and efficacy. www.nature.com/Scientific Reports. 
2019; 9:200 DOI:10.1038/s41598-018-[ZIP_CODE]-y.
12Kurz R and Blaas K. Use of dronabinol (delta -9-THC) in autism: A prospective single-case-
study with an early infantile autis tic child. Cannabinoids 2010;5(4):4â€“6.
13Arseneault L, Cannon M, Poulton R, et al., Canna bis use in adolescence and risk for adult 
psychosis: longitudinal prospective study, BMJ. 2002; 325(7374):1212â€“3.
14Anagnostou E, Jones N, Huerta M, et al. Measuring social communi cation behaviors as a 
treatment endpoint in individuals with au tism spectrum disorder. Autism, 2015; 19(5) 622â€“
36.
15Bolognani F, del Valle Rubido M, Squassante L, et al. A phase [ADDRESS_31079] shows improved adaptive behaviors in men with autism spectrum disorder. Sci. Transl. Med., 2019;11: eaat7838.
16Aman  MG and Singh NN.  Aberrant Beha viour Checklist Manual, second edition. 2017.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 82 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1517The Voice of The Patient, Autis m, Report Date: January 2018: 
https://www.fda.gov/media/111099/download.
18Guy W. ECDEU Assessment manual for psychopharmacology. Revised, 1976.
19Lecavalier L, Wood JJ, Halladay AK, et al. M easuring anxiety as a treatment endpoint in 
youth with autism spectrum disorder.J Autism Dev Disord. 2014 May; 44(5): 1128â€“43.doi: 
0.1007/s10803-013-1974-9
20ICH Harmonised Tripartite Guideline: Guidance on Nonclinical Safety Studies for the 
Conduct of Human Clinical Tr ials and Marketing Authorization for Pharmaceuticals 
M3(R2). June 2009.
21Clinical Trial Facilitation Gr oup: Recommendations related to  contraception and pregnancy 
testing in clinical trials.  September 2014.
22Lam KSL, Aman MG. The Repetitive Behavior Scale-Revised: Independent Validation in 
Individuals with Autism Spectrum Disord ers. J Autism Dev Disord. 2007;37:855-856. doi 
10.1007/s10803-006-0213-z
23Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: 
comparisons to mental retardati on. J Autism Dev Disord, 2000; 30(3):237â€“43.
24Hoefman R, Payakachat N, van Exel J, et al. Caring for a child with autism spectrum disorder and parentsâ€™ quality of life:  Application of the CarerQol . J Autism Dev Disord. [ADDRESS_31080]; 
44 (8):1933â€“45.
25World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. October 2013.
26ICH Harmonised Guideline: Integrated a ddendum to ICH E6(R1) Guideline for Good 
Clinical Practice E6(R2). November 2016.
27US Food and Drug Administration Code of Fe deral Regulations Title 21 (Food and Drugs) 
Part 312â€”Investigational New Drug Application. 01 April 2014.
28US Food and Drug Administration Code of Fe deral Regulations Title 21 (Food and Drugs) 
Part 50-Protection of Hu man Subjects.  April 2018.
29US Food and Drug Administration Code of Fe deral Regulations Title 21 (Food and Drugs) 
Part 56-Institutional Revi ew Boards.  April 2018.
30Directive 2001/20/EC of the European Parliament and of the Council of [ADDRESS_31081] of clinical trials on 
medicinal products for human use.  Official  Journal of the European Communities L 121, 
1/5/2001 p. 34â€“44.
31Commission Directive 2005/28/EC of 08 April 2005 laying down the princi ples and detailed 
guidelines for GCP as regards investigational medicinal products for human use, as well as 
the requirements for authorisation of the ma nufacturing or importati on of such products.  
Official Journal of the European Union L 91, 9/4/2005 p. 13â€“19.
32US Food and Drug Administration Guidance for Clin ical Investigators, Sponsors, and IRBs.  
Adverse Event Reporting to IRBs- Improvi ng Human Subject Protection.  January 2009.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 83 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep1533Fung LK, Mahajan R, Nozzolillo A, et al. Pharma cologic treatment of se vere irritability and 
problem behaviors in autism: a systematic  review and meta-ana lysis. Pediatrics, 
2016;137(s2):e20152851K.
34World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research 
Involving Human Subjects. October 2013.
35[LOCATION_006] Statutory Instrument 2004 No. 1031: The Me dicines for Human Use (Clinical Trials) 
Regulations 2004.  May 2004.
36[LOCATION_006] Statutory Instrument 2012 No. 1916: The Human Medicines Regulations 2012.  August 2012.
37[LOCATION_006] Statutory Instrument 2006 No. 1928: The Me dicines for Human Use (Clinical Trials) 
Amendment Regulations 2006.  August 2006. 
38[LOCATION_006] Statutory Instrument 2008 No. 941: The Medi cines for Human Use (Clinical Trials) and 
Blood Safety and Quality (Amendm ent) Regulations 2008.  May 2008.
39US Food and Drug Administration Code of Fe deral Regulations Title 21 (Food and Drugs) 
Part 11-Electronic records; Electronic signatures (Subpart Bâ€”Electronic Records). April 
2018.
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 84 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15APPENDIX 1 SCHEDULE OF ASSESSMENTS
Schedule of Assessments
Period ScreeningTreatment Period End of 
TaperFollow-upn
Visit Visit 1aVisit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visits 
7Visit 8
EoT/WDVisit 9 Visit 10
Visit Type Clinic Clinic Telephone TelephoneClinic or 
Video 
Call and 
Home 
Nurse*TelephoneClinic or 
Video 
Call ClinicClinic or 
Video 
Call and 
Home 
Nurse*Telephone
Day -14 to -7 1 7 (Â± 3) 14 (Â± 3)29 (Â± 
3)43 (Â± 3)57 (Â± 
3)85 (Â± 3)V8 + 7 
(+ 3)V9 + 14 
(+ 3)
Informed consent/assent X
Demographics X
Medical historybX
Inclusion and exclusion criteria X X
AE review X X X X X X X X X X
SAE review X X X X X X X X X X
Concomitant medication reviewcX X X X X X X X X X
Test for drugs of abuse X
C-SSRS X X X X X X
Vital signsdX X X X X
Full physical examination X X
Height X
Weight X X
BMI X
12-lead ECGeX X
Safety laboratory assessmentsfX XIf not 
taperingX
UrinalysisgXIf not 
taperingX
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 85 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Period ScreeningTreatment Period End of 
TaperFollow-upn
Visit Visit 1aVisit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visits 
7Visit 8
EoT/WDVisit 9 Visit 10
Visit Type Clinic Clinic Telephone TelephoneClinic or 
Video 
Call and 
Home 
Nurse*TelephoneClinic or 
Video 
Call ClinicClinic or 
Video 
Call and 
Home 
Nurse*Telephone
Serum pregnancy test (WOCBP 
only)XIf not 
taperingX
Trial treatment X X X X X X X X
RandomizationiX
WASI-II (if required)lX
ADOS-2 (if required) X
ABCjX X X X X
Vineland-3j,kX X X X
CGI-SkX X X X X
CGI-IkX X X
IMP dispensingmX X X
IMP review X X X
Dosing diary completion (daily) X
IMP dosing compliance reviewoX X X X X X
Abbreviations: ABC = Aberrant Behavior Chec klist; ADOS-2 = Autism Diagnostic Observati onal Schedule; AE = adverse events;  
CGI-I = Clinical Global Impr ession Improvement; CGI-
S = Clinical Global Impression Severity; C-SSRS = Columbia-Suicide  Severity Rating Scale; DSM-5 = Diagnostic and Statistical Man ual of Mental Disorders, 
5th Edition; ECG = 12-lead electrocardiogram; EoT = End of Treatment; IMP = investigational medicinal product accountability;  

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 86 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15 RTSM = Randomization and Trial Management Sys tem; SAE = seriou s 
adverse events; WASI-II = Wechsler Abbreviated Scale of Intellig ence Scale Second Edition; WD = w ithdrawal; WOCBP = women of ch ildbearing potential. 
*For visits carried out remotely, home nurse assessments include: collection of blood and urine samples (including urine dipstic k), and vital signs. 
aScreening procedures may be performed over 2 days, if needed; both days must fall within the -[ADDRESS_31082] the condition under study, is ongoing on 
entry into the trial, and information on ASD history, including known etiologies. Patient has a diagnosis of ASD as per DSM-5 cr iteria for ASD, confirmed 
by [CONTACT_31656]-2 criteria (conducted within 2 years at the trial site or at screening).
cAll current and recent medication/therapy, i.e., taken within [ADDRESS_31083] remain at stable doses throughout the trial; howe ver, doses may be changed in response to a safety concern. 
dIncludes body temperature, pulse rate, an d respi[INVESTIGATOR_31654] n in a sitting position at rest for 5 minutes .
e Performed after 5 minutes in a supi[INVESTIGATOR_31655] a physician. 
f Includes hematology and biochemistry (including liver chemistries). Coagulation only at Visit 1; thereafter only as an unschedul ed assessment if ALT or 
AST > 3 Ã— ULN). If the patient in not tapering (and therefore will not attend Visit 9), clinical laboratory sampling is to be ca rried out at Visit 8. Details are 
provided in Table 9.1-1.
g Urinalysis to be performed provided urine can be obtained. Urine samples for biochemistry will be analyzed at the trial site ( or by [CONTACT_31678]) by [CONTACT_2363] 
a dipstick with any relevant findings being sent for further urinalysis at the central laboratory (urinalysis, microscopy, cult ure and sensitivity, as applicable). 
Details are provided in Table 9.1-1.
h TKHVDPSOHPXVWEHFROOHFWHGKRXUVÃ­KRXUVVLQFHOD st IMP dose and before the patientâ€™s next dose. The time of sample collection, the time of 
previous IMP dose, and time and type of meal (snack, standard meal, high fat) consumed by [CONTACT_31720] I MP dose will be collected.. 
To minimize discomfort samples should be collected together with the safety laboratory sample collection.
iThe RTSM system will be used to assign pati ents to treatment arms, including randomization.
jCaregivers questionnaires are to be completed by [CONTACT_31721] (nominated at Visit 1. The same identified caregiv er is to complete the clinical 
interviews (Vineland-3 and ).
kInvestigator questionnaires/interv iews are to be completed for each patient by [CONTACT_31722] (CGI-S, CGI-I, Vineland-3, and ).
l  Patients functional assessments, i.e., the WASI-II, ADOS-2,  should be performed prior to  any invasive assessments 
being carried out. All assessments should reflect the patientâ€™s regular state; therefore, it should be ensured the patient had adequate time to settle prior to 
each assessment. WASI-II required if score w ithin 1 year of screening is not availabl e. ADOS-2 required if not performed at the tr ial site within 2years. 
During special circumstances (e.g., COVID-19 pandemic) where the ADOS -2 cannot be performed due to site restrictions (e.g., man datory use of face 
masks), eligibility can be confirmed using the Autism Diagnostic Interview, Revised (ADI-R).
mIn cases where Visits 5, or 9 are car ried out at home, secure IMP delivery and collection will be organized. 
n  If the patient did not enter the Taper Period, then Safety Follow-up occurs 14 days after Visit 8.
o  Dosing diary (completion and volumes taken) and time of IMP taken in relation to food will be reviewed

Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 87 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15APPENDIX [ADDRESS_31084] 
of all investigators will be maintained within the GW master files (electronically and added to 
the trial master file at the end of the trial).
Appendix 2.[ADDRESS_31085] Details
Pharmacovigilance Depa rtment â€” SAE Reporting: Fax: +44 (0)1223 233 319
[LOCATION_003] Toll-free Fax:
+[PHONE_491]
Tel: +44 (0)1223 233 410
Sponsor: GW Research Ltd
Sovereign HouseVision ParkChivers Way
Histon
Cambridge CB24 9BZ[LOCATION_008]
Tel: +44 (0) 1223 266 800
Fax: +44 (0) [ADDRESS_31086] Number& Clinical Project Manager:Please refer to the sponsor and 
Related Contact [CONTACT_31723].
Clinical Trial Supplies: G-Pharm Ltd
Tel: +44 (0) 1795 435 029Fax: +44 (0) 1795 475 439
At the time of protocol producti on, the CROs, and the clinical and bioanalytical laboratories for 
the trial had not been confirmed. A corresponding lis t will be maintained w ithin the GW master 
files (electronically and added to the trial master file at the end of the trial):
Medical Advisor & Clinical Project Ma nager: Please refer to the sponsor and 
Related Contact [CONTACT_31724].
Clinical Trial Supplies: G-Pharm Ltd
Tel: +44 (0) 1795 435 029
Fax: +44 (0) 1795 475 439
Study Code: GWND19189
IND Number: 150775
Protocol Version 2.0, 24 Nov 2020
Confidential Page 88 of 88
Clinical Protocol Template (Phase 2â€“4) V1, 24Sep15Appendix 2.[ADDRESS_31087], Reading, RG2 6UU
Main Office Address
1700 Perimeter Park DriveMorrisville, NC [LOCATION_003] [ZIP_CODE]